Horizon Therapeutics Public (HZNP) 10-K 13 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 11, 2014	Jun. 28, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'HZNP	'	'
Entity Registrant Name	'HORIZON PHARMA, INC.	'	'
Entity Central Index Key	'0001492426	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	67,733,417	'
Entity Public Float	'	'	$128,221,687

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
CURRENT ASSETS:	'	'
Cash and cash equivalents	$80,480	$104,087
Restricted cash	738	800
Accounts receivable, net	15,958	3,463
Inventories, net	8,701	5,245
Prepaid expenses and other current assets	4,888	3,323
Total current assets	110,765	116,918
Property and equipment, net	3,780	3,725
Intangible assets, net	131,094	68,892
Other assets	6,957	4,449
TOTAL ASSETS	252,596	193,984
CURRENT LIABILITIES:	'	'
Accounts payable	9,921	5,986
Accrued expenses	24,049	16,784
Accrued royalties	8,010	'
Deferred revenues-current portion	1,330	2,230
Notes payable-current portion	'	11,935
Total current liabilities	43,310	36,935
LONG-TERM LIABILITIES:	'	'
Convertible debt, net	110,762	'
Derivative liability	109,410	'
Accrued royalties	24,982	'
Notes payable, net of current	110,762	36,866
Deferred revenues, net of current	9,686	9,554
Deferred tax liabilities, net	3,362	4,408
Other long term liabilities	166	243
Total long-term liabilities	258,368	51,071
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' EQUITY:	'	'
Common stock, $0.0001 par value; 200,000,000 shares authorized; 66,097,417 and 61,722,247 shares issued and outstanding at December 31, 2013 and 2012, respectively	7	6
Additional paid-in capital	410,430	417,455
Accumulated other comprehensive loss	-2,403	-3,372
Accumulated deficit	-457,116	-308,111
Total stockholders' (deficit) equity	-49,082	105,978
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$252,596	$193,984

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	66,097,417	61,722,247
Common stock, shares outstanding	66,097,417	61,722,247

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
REVENUES:	'	'	'
Gross sales	$102,995	$22,978	$6,939
Sales discounts and allowances	-28,979	-4,134	-12
Net sales	74,016	18,844	6,927
Cost of goods sold	14,625	11,875	7,267
Gross profit (loss)	59,391	6,969	-340
OPERATING EXPENSES:	'	'	'
Research and development	10,084	16,837	15,358
Sales and marketing	68,595	49,561	20,314
General and administrative	23,566	19,444	15,008
Intangible impairment charge	'	'	69,621
Total operating expenses	102,245	85,842	120,301
Operating loss	-42,854	-78,873	-120,641
OTHER (EXPENSE) INCOME, NET:	'	'	'
Interest expense, net	-39,178	-14,525	-6,284
Foreign exchange gain (loss)	1,206	489	-1,023
Loss on derivative fair value	-69,300	'	'
Other, net	'	-56	'
Total other expense, net	-107,272	-14,092	-7,307
Loss before benefit for income taxes	-150,126	-92,965	-127,948
BENEFIT FOR INCOME TAXES	-1,121	-5,171	-14,683
NET LOSS	-149,005	-87,794	-113,265
NET LOSS PER COMMON SHARE - Basic and diluted	($2.34)	($2.26)	($12.56)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING - Basic and diluted	63,657,924	38,871,422	9,014,968
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX	'	'	'
Foreign currency translation adjustments	969	416	-1,559
Other comprehensive income (loss)	969	416	-1,559
COMPREHENSIVE LOSS	($148,036)	($87,378)	($114,824)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
In Thousands, except Share data
Beginning balance at Dec. 31, 2010	$97,056	$2	'	$206,336	($2,230)	($107,052)
Beginning balance, shares at Dec. 31, 2010	'	24,961,340	1,490,551	'	'	'
Common stock issuance in public offering, net of underwriting fees and issuance costs	41,745	'	1	41,744	'	'
Common stock issuance in public offering, net of underwriting fees and issuance costs, shares	'	'	5,500,000	'	'	'
Issuance of common stock in conjunction with the conversion of bridge notes payable	18,156	'	'	18,156	'	'
Issuance of common stock in conjunction with the conversion of bridge notes payable, shares	'	'	2,017,242	'	'	'
Conversion of convertible preferred stock to common stock	'	-2	1	1	'	'
Conversion of convertible preferred stock to common stock, shares	'	-24,961,340	10,514,431	'	'	'
Issuance of common stock in conjunction with option exercises and ESPP purchases	124	'	'	124	'	'
Issuance of common stock in conjunction with option exercises and ESPP purchases, shares	'	'	24,172	'	'	'
Stock-based compensation	2,530	'	'	2,530	'	'
Issuance of common stock in conjunction with warrant exercises, shares	'	'	81,348	'	'	'
Issuance of common stock in connection with notes payable amendment	1,124	'	'	1,124	'	'
Currency translation adjustment	-1,558	'	'	'	-1,558	'
Net loss	-113,265	'	'	'	'	-113,265
Ending balance at Dec. 31, 2011	45,912	'	2	270,015	-3,788	-220,317
Ending balance, shares at Dec. 31, 2011	'	'	19,627,744	'	'	'
Issuance of common stock in conjunction with equity financing offerings, net of underwriting fees and issuance costs	128,079	'	4	128,075	'	'
Issuance of common stock in conjunction with equity financing offerings, net of underwriting fees and issuance costs, shares	'	'	38,672,579	'	'	'
Issuance of common stock in conjunction with vesting of restricted stock units and stock option exercises, shares	'	'	74,050	'	'	'
Issuance of common stock in conjunction with option exercises and ESPP purchases	287	'	'	287	'	'
Issuance of common stock in conjunction with option exercises and ESPP purchases, shares	'	'	106,955	'	'	'
Stock-based compensation	4,661	'	'	4,661	'	'
Issuance of common stock in conjunction with warrant exercises	154	'	'	154	'	'
Issuance of common stock in conjunction with warrant exercises, shares	'	'	1,990,919	'	'	'
Issuance of warrants in connection with notes payable	9,188	'	'	9,188	'	'
Issuance of common stock in connection with notes payable amendment	5,075	'	'	5,075	'	'
Issuance of common stock in connection with notes payable amendment, shares	'	'	1,250,000	'	'	'
Currency translation adjustment	416	'	'	'	416	'
Net loss	-87,794	'	'	'	'	-87,794
Ending balance at Dec. 31, 2012	105,978	'	6	417,455	-3,372	-308,111
Ending balance, shares at Dec. 31, 2012	'	'	61,722,247	'	'	'
Issuance of common stock in conjunction with equity financing offerings, net of underwriting fees and issuance costs	5,998	'	1	5,997	'	'
Issuance of common stock in conjunction with equity financing offerings, net of underwriting fees and issuance costs, shares	'	'	2,448,575	'	'	'
Issuance of common stock in conjunction with vesting of restricted stock units and stock option exercises	161	'	'	161	'	'
Issuance of common stock in conjunction with vesting of restricted stock units and stock option exercises, shares	'	'	340,029	'	'	'
Issuance of common stock in conjunction with option exercises and ESPP purchases	478	'	'	478	'	'
Issuance of common stock in conjunction with option exercises and ESPP purchases, shares	'	'	225,820	'	'	'
Stock-based compensation	5,014	'	'	5,014	'	'
Issuance of common stock in conjunction with warrant exercises, shares	'	'	1,360,746	'	'	'
Purchase of capped calls	-18,675	'	'	-18,675	'	'
Currency translation adjustment	969	'	'	'	969	'
Net loss	-149,005	'	'	'	'	-149,005
Ending balance at Dec. 31, 2013	($49,082)	'	$7	$410,430	($2,403)	($457,116)
Ending balance, shares at Dec. 31, 2013	'	'	66,097,417	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($149,005)	($87,794)	($113,265)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization expense	9,310	5,538	4,199
Stock-based compensation	5,014	4,661	2,530
Loss on derivative revaluation	69,300	'	'
Intangible impairment charge	'	'	69,621
Paid in kind interest expense	2,225	2,607	'
Amortization of debt discount, deferred financing costs and debt extinguishment	17,245	2,740	2,708
Foreign exchange (gain) loss	-1,206	-489	1,023
Loss on disposal of assets	'	76	'
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-12,491	-1,087	-1,817
Inventories	-3,426	-4,022	-923
Prepaid expenses and other current assets	-1,240	-543	-1,897
Accounts payable	3,908	-2,209	5,643
Accrued expenses	7,942	7,052	3,215
Deferred revenues	-1,145	2,616	3,237
Deferred tax liabilities	-1,186	-5,206	-15,778
Other non-current assets and liabilities	468	-581	-36
Net cash used in operating activities	-54,287	-76,641	-41,540
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Purchases of property and equipment	-1,198	-1,336	-1,604
Change in restricted cash	63	-50	-550
VIMOVO asset acquisition	-35,000	'	'
Net cash used in investing activities	-36,135	-1,386	-2,154
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from the issuance of convertible debt, net of issuance costs	143,598	'	'
Purchase of capped calls	-18,675	'	'
Proceeds from the issuance of common stock under an ATM agreement, net of issuance costs	5,998	'	'
Proceeds from issuance of common stock in initial public offering, net of underwriting fees and issuance costs	'	'	44,678
Proceeds from issuance of bridge notes payable to related parties	'	'	6,766
Proceeds from equity finance offerings, net of offering costs	'	128,077	'
Proceeds from the issuance of notes payable	'	55,578	16,651
Proceeds from the issuance of common stock	639	441	124
Repayment of notes payable	-64,844	-19,788	-13,067
Net cash provided by financing activities	66,716	164,308	55,152
Effect of foreign exchange rate changes on cash	99	-160	1,124
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-23,607	86,121	12,582
CASH AND CASH EQUIVALENTS, beginning of the year	104,087	17,966	5,384
CASH AND CASH EQUIVALENTS, end of the year	80,480	104,087	17,966
Supplemental cash flow information:	'	'	'
Cash paid for interest	8,573	7,554	2,757
Cash paid for income taxes	44	57	'
Cash paid for debt extinguishment interest and penalties	12,152	2,124	440
Significant non-cash investing activities:	'	'	'
Contingent liabilities assumed in acquisition	32,992	'	'
Intangible assets acquired in acquisition	$67,705	'	'

The_Company

The Company	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
The Company	'
	NOTE 1 – THE COMPANY
	Horizon Pharma, Inc. (the “Company”) was incorporated in Delaware on March 23, 2010. On April 1, 2010, the Company became a holding company that operates primarily through its two wholly-owned subsidiaries, Horizon Pharma USA, Inc. (formerly known as Horizon Therapeutics, Inc.), a Delaware corporation, and Horizon Pharma AG (formerly known as Nitec Pharma AG, “Nitec”), a company organized under the laws of Switzerland which was acquired by the Company on April 1, 2010 in exchange for newly-issued shares of Horizon Pharma, Inc. Horizon Pharma AG owns all of the outstanding share capital of its wholly-owned subsidiary, Horizon Pharma GmbH, a company organized under the laws of Germany (formerly known as Nitec Pharma GmbH), through which Horizon Pharma AG conducts most of its European operations. Unless the context indicates otherwise, the “Company” refers to Horizon Pharma, Inc. and its subsidiaries taken as a whole.
	The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company developed DUEXIS and RAYOS/LODOTRA, and it acquired the U.S. rights to VIMOVO from AstraZeneca AB (“AstraZeneca”) in November 2013. The Company’s strategy is to develop, acquire or in-license additional innovative medicines or acquire companies where the Company can execute a targeted commercial approach among specific target physicians, such as primary care physicians, orthopedic surgeons and rheumatologists, while taking advantage of its commercial strengths and the infrastructure that has been put in place.
	On April 23, 2011, the U.S. Food and Drug Administration (“FDA”) approved DUEXIS, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. DUEXIS is indicated for the relief of signs and symptoms of rheumatoid arthritis (“RA”), osteoarthritis (“OA”) and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications. In the second half of 2011, the Company hired its initial commercial organization, including approximately 80 sales representatives, completed sales force training and began detailing DUEXIS to physicians in December 2011. In June 2012, the Company licensed DUEXIS rights in Latin America to Grünenthal S.A., a private company focused on the promotion of pain products. In the third quarter of 2012, the Company expanded its sales force to approximately 150 representatives and has subsequently further expanded its sales force to approximately 290 representatives, most recently by adding approximately 115 representatives in connection with the Company’s acquisition of the U.S. rights to VIMOVO in November 2013. In March 2013, the Company announced that the United Kingdom (“UK”) Medicines and Healthcare Products Regulatory Agency granted a National Marketing Authorization for DUEXIS in the UK. The Company will seek to license rights to DUEXIS in Europe to a commercial partner or partners. Given the current state of the market in Europe for pain products and the revenue being generated there by existing branded non-steroidal anti-inflammatory drugs (“NSAIDs”), the Company does not expect a material level of sales from DUEXIS in European markets.
	The Company’s second approved product in the United States, RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. On July 26, 2012, the FDA approved RAYOS for the treatment of RA, polymyalgia rheumatica (“PMR”), psoriatic arthritis, ankylosing spondylitis (“AS”), asthma and chronic obstructive pulmonary disease and a number of other conditions. The Company is focusing its promotion of RAYOS in the United States on rheumatology indications, including RA and PMR. The Company began detailing RAYOS to a subset of U.S. rheumatologists in December 2012 and began the full launch in late January 2013 to the majority of U.S. rheumatologists and key primary care physicians. LODOTRA is currently marketed outside the United States by the Company’s distribution partner, Mundipharma International Corporation Limited (“Mundipharma”).
	On November 18, 2013, the Company entered into agreements with AstraZeneca pursuant to which the Company acquired from AstraZeneca and its affiliates certain intellectual property and other assets, and assumed from AstraZeneca and its affiliates certain liabilities, each with respect to VIMOVO, and obtained rights to develop other pharmaceutical products that contain gastroprotective agents in a single fixed combination oral solid dosage form with NSAIDs in the United States. VIMOVO (naproxen/esomeprazole magnesium) is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a proton pump inhibitor, layer surrounding the core. VIMOVO was originally developed by Pozen Inc. (“Pozen”) together with AstraZeneca pursuant to an exclusive global collaboration and license agreement under which AstraZeneca and Pozen agreed to co-develop VIMOVO and AstraZeneca obtained exclusive rights to commercialize VIMOVO worldwide. On April 30, 2010, the FDA approved VIMOVO for the relief of the signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID associated gastric ulcers.
	Under the asset purchase agreement with AstraZeneca, the Company acquired certain existing assets and rights necessary to commercialize VIMOVO in the United States including, among other things, the investigational new drug application (“IND”) and new drug application (“NDA”) for VIMOVO in the United States, AstraZeneca’s interest in certain patents covering VIMOVO in the United States and certain promotional materials and records related to VIMOVO in the United States. In addition, AstraZeneca assigned to the Company its amended and restated collaboration and license agreement for the United States with Pozen, pursuant to which AstraZeneca has in-licensed from Pozen certain patents and know-how of Pozen covering VIMOVO in the United States. For accounting purposes, the acquisition of the U.S. rights to VIMOVO was treated as a business combination. Collectively, these transactions are referred to as the “VIMOVO Acquisition.”
	In December 2013, as a result of its acquisition of the U.S. rights to VIMOVO, the Company began the expansion of its sales force to approximately 250 primary care representatives and 40 rheumatology sales specialists and recognized revenues under the transition agreement with AstraZeneca. The Company announced the availability of Horizon-labeled VIMOVO on January 2, 2014. The Company completed the hiring and training of its expanded sales force in January 2014 and began selling VIMOVO in early February 2014. The Company’s primary care representatives will promote DUEXIS in a primary position to physician targets who are high branded NSAID prescribers and are also prescribers of DUEXIS and ibuprofen and will promote VIMOVO in a second position among these target physicians. The Company’s primary care representatives will promote VIMOVO in a primary position to physician targets who are high branded NSAID prescribers and are also prescribers of VIMOVO and naproxen, and they will promote DUEXIS in a second position among these target physicians. The Company’s analysis indicates that there is an approximate 30% overlap of physician targets who prescribe both DUEXIS and VIMOVO. In those cases, individual target-by-target promotional plans will be executed and both DUEXIS and VIMOVO will be promoted to these targets. The Company has also expanded its rheumatology specialty sales force from 25 sales specialists to approximately 40 sales specialists, with these specialist representatives promoting RAYOS and VIMOVO to rheumatologists. The Company has also included VIMOVO in its Prescriptions-Made-Easy specialty pharmacy program, along with DUEXIS and RAYOS, and offers co-pay assistance for all of its marketed products to ensure patients receive them at a reasonable out-of-pocket cost.
	Revision of Prior Period Financial Statements
	In the course of preparing the Company’s Consolidated Statements of Comprehensive Loss for this Annual Report on Form 10-K, the Company determined that there had been a misclassification of certain fees in its financial statements for the previously reported quarters ended March 31, 2012 and 2013, June 30, 2012 and 2013 and September 30, 2012 and 2013, as well as the Company’s annual financial statements for the year ended December 31, 2012 (collectively, the “Affected Financial Statements”).
	The Affected Financial Statements classified wholesaler service fees as cost of goods sold. The Company determined that these fees should be classified as sales discounts and allowances, which was a reduction in revenue instead of an increase in cost of goods sold and have revised all identified prior period misclassifications in the periods in which they originated. The revision had no impact on the Company’s reported gross profit, net loss or cash flows.
	In evaluating whether the Company’s previously issued consolidated financial statements were materially misstated, the Company considered the guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections, ASC Topic 250-10-S99-1, Assessing Materiality, and ASC Topic 250-10-S99-2, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements. The Company concluded that these misstatements were not material, individually or in the aggregate, to any of the prior reporting periods, and therefore, amendments of previously filed reports were not required. As such, the revisions are reflected in the financial information of the applicable prior periods and will be reflected in future filings containing such financial information.
	The following table includes selected line items from our financial statements illustrating the effect of the revision:
		As Reported			Adjustment			As Revised
		(in thousands)
	Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2012
	Sales discounts and allowances		(384	)		(38	)		(422	)
	Net Sales		2,523			(38	)		2,485
	Cost of goods sold		2,067			(38	)		2,029
	Consolidated Statements of Comprehensive Loss for the Three Months Ended June 30, 2012
	Sales discounts and allowances		(767	)		(160	)		(927	)
	Net Sales		3,841			(160	)		3,681
	Cost of goods sold		2,855			(160	)		2,695
	Consolidated Statements of Comprehensive Loss for the Three Months Ended September 30, 2012
	Sales discounts and allowances		(790	)		(202	)		(992	)
	Net Sales		6,521			(202	)		6,319
	Cost of goods sold		3,810			(202	)		3,608
	Consolidated Statements of Comprehensive Loss for the Three Months Ended December 31, 2012
	Sales discounts and allowances		(1,405	)		(388	)		(1,793	)
	Net Sales		6,747			(388	)		6,359
	Cost of goods sold		3,931			(388	)		3,543
	Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2013
	Sales discounts and allowances		(1,527	)		(478	)		(2,005	)
	Net Sales		9,171			(478	)		8,693
	Cost of goods sold		4,247			(478	)		3,769
	Consolidated Statements of Comprehensive Loss for the Three Months Ended June 30, 2013
	Sales discounts and allowances		(5,383	)		(1,123	)		(6,506	)
	Net Sales		12,254			(1,123	)		11,131
	Cost of goods sold		3,517			(1,123	)		2,394
	Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2013
	Sales discounts and allowances		(6,910	)		(1,601	)		(8,511	)
	Net Sales		21,425			(1,601	)		19,824
	Cost of goods sold		7,764			(1,601	)		6,163
	Consolidated Statements of Comprehensive Loss for the Three Months Ended September 30, 2013
	Sales discounts and allowances		(5,306	)		(2,106	)		(7,412	)
	Net Sales		26,218			(2,106	)		24,112
	Cost of goods sold		5,313			(2,106	)		3,207
	Consolidated Statements of Comprehensive Loss for the Nine Months Ended September 30, 2013
	Sales discounts and allowances		(12,216	)		(3,707	)		(15,923	)
	Net Sales		47,643			(3,707	)		43,936
	Cost of goods sold		13,077			(3,707	)		9,370
	The financial statements are prepared on a going concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business. As of December 31, 2013, the Company had cash and cash equivalents totaling $80,480. The Company believes that it has sufficient liquidity and capital resources to reach cash flow positive operations based on the Company’s current expectations of continued revenue growth. However, the Company is highly dependent in the near term on the commercial success of DUEXIS, VIMOVO and RAYOS in the U.S. market. Additionally, the Company has convertible debt which may be required to be settled in cash up to the principal amount upon certain circumstances outside the control of the Company, prior to obtaining stockholder approval to issue enough shares to cover the conversion option in shares of its common stock.
	The Company has incurred net operating losses and negative cash flows from operations since its inception. In order to continue its operations, the Company must generate sufficient revenue and achieve profitable operations. If that does not occur, the Company’s plan is to obtain additional debt or equity financing. There can be no assurance, however, that such financing will be available or on terms acceptable to the Company. These uncertainties and lack of commercial operating history raise substantial doubt about the Company’s ability to continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“GAAP”) and in accordance with the instructions for Form 10-K and Article 3 of Regulation S-X. The consolidated financial statements include the accounts of the Company and its wholly-owned consolidated subsidiaries.
	Principles of Consolidation
	The consolidated financial statements include the Company’s accounts and those of its wholly-owned subsidiaries: Horizon Pharma USA, Inc. in Deerfield, IL, Horizon Pharma AG in Reinach, Switzerland and Horizon Pharma GmbH in Mannheim, Germany. All intercompany accounts and transactions have been eliminated.
	Segment Information
	The Company operates as one segment. Management uses one measure of profitability and does not segment its business for internal reporting.
	Use of Estimates
	The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Foreign Currency Translation and Transactions
	The reporting currency of the Company and its subsidiaries is the U.S. dollar.
	The U.S. dollar is the functional currency for the Company’s U.S. based businesses and the Euro is the functional currency for its subsidiaries in Switzerland and Germany. Foreign currency-denominated assets and liabilities of these subsidiaries are translated into U.S. dollars based on exchange rates prevailing at the end of the period, revenues and expenses are translated at average exchange rates prevailing during the corresponding period, and stockholders’ equity (deficit) accounts are translated at historical exchange rates as of the date of any equity transaction. The effects of foreign exchange gains and losses arising from the translation of assets and liabilities of those entities where the functional currency is not the U.S. dollar are included as a component of accumulated other comprehensive income (loss).
	Gains and losses resulting from foreign currency translations are reflected within the Company’s results of operations. During the years ended December 31, 2013 and 2012, the Company recorded gains from foreign currency translations of $1,206 and $489, respectively, compared to a loss from foreign currency translations during the year ended December 31, 2011 of $1,023. The Company does not currently utilize and has not in the past utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure.
	Revenue Recognition
	Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured. Some of the Company’s agreements contain multiple elements and in accordance with these agreements, the Company may be eligible for upfront license fees, marketing or commercial milestones and payment for product deliveries.
	Revenue from upfront license fees
	The Company recognizes revenues from the receipt of non-refundable, upfront license fees. In situations where the licensee is able to obtain stand-alone value from the license and no further performance obligations exist on the Company’s part, revenues are recognized on the earlier of when payments are received or collection is reasonably assured. Where continuing involvement by the Company is required in the form of technology transfer, product manufacturing or technical support, revenues are deferred and recognized over the term of the agreement.
	Revenue from milestone receipts
	Milestone payments are recognized as revenue based on achievement of the associated milestones, as defined in the relevant agreements. Revenue from a milestone achievement is recognized when earned, as evidenced by acknowledgment from the Company’s partner, provided that (1) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, (2) the milestone represents the culmination of an earnings process and (3) the milestone payment is non-refundable. If all of these criteria are not met, revenue from the milestone achievement is recognized over the remaining minimum period of the Company’s performance obligations under the agreement.
	Revenue from product deliveries
	The Company recognizes revenue from the delivery of its products when delivery has occurred, title has transferred, the selling price is fixed or determinable, collectability is reasonably assured and the Company has no further performance obligations. In addition, revenue is only recognized when the right of return no longer exists (which is the earlier of the product being dispensed through patient prescriptions or the expiration of the right of return) or when product returns can be reasonably estimated. Prior to October 2012, revenue from products sold to the Company’s wholesale distributors and retail chains was recognized based on the amount of product sold through to the end consumer. Since October 2012, due to the Company’s ability to reasonably estimate and determine allowances for product returns, rebates and discounts, the Company has been recognizing DUEXIS and RAYOS revenue at the point of sale to wholesale pharmaceutical distributors and retail chains. The Company has been recognizing VIMOVO revenue at the point of sale, consistent with its revenue recognition of DUEXIS and RAYOS, given the availability of prior VIMOVO product return data.
	The Company anticipates revenues will continue to result from distribution, marketing, manufacturing and supply agreements with third parties in Europe and certain Asian, Latin American and other countries with respect to LODOTRA.
	Under the manufacturing and supply agreements with Mundipharma Medical Company (“Mundipharma Medical”), Mundipharma Medical agreed to purchase LODOTRA exclusively from the Company at a price based on a specified percentage of the average net selling price (“ANSP”) for sales in a given country, subject to a minimum price. Mundipharma Medical has a nine-month period from purchase date to request an ANSP adjustment. If the ANSP is lower than the actual purchase price, then Mundipharma Medical would receive a price adjustment. Products sold to Mundipharma Medical are recognized upon delivery at the minimum price, as no contractual right of return exists. The difference between the actual selling price and the minimum price is recorded as deferred revenue until such time as adjustments for product returns, rebates and discounts can be reliably estimated or the nine-month ANSP adjustment period passes, at which time any previously deferred revenue would be recognized as revenue. As of December 31, 2013 and 2012, deferred revenues related to the sale of LODOTRA were $615 and $1,939, respectively. Additionally, as of December 31, 2013 and 2012, deferred revenues related to milestone and upfront payments received under existing agreements were $8,682 and $8,175, respectively.
	In December 2011, the Company began recognizing revenues from the sale of DUEXIS following its commercial launch in the United States. DUEXIS is currently sold to wholesale pharmaceutical distributors and to several national and regional retail chains. Until the Company could reliably estimate returns, the Company determined that shipment of products to wholesale pharmaceutical distributors and regional retail chains did not meet the criteria for revenue recognition at the time of shipment. The Company therefore deferred DUEXIS revenue recognition until the right of return no longer existed, which was the earlier of DUEXIS being dispensed through patient prescriptions or the expiration of the right of return (twelve months after the expiration date of the product).
	During the fourth quarter of 2012, the Company changed from recognizing DUEXIS revenue upon product being dispensed through patient prescriptions to recognizing revenue when product is sold into the wholesale pharmaceutical distributor and retail chain channel. This change was based on approximately one year of minimal product return quantities and an enhanced ability and historical experience upon which to monitor DUEXIS inventory levels in the distribution channel and to assess the relative risk of potential product returns. The Company believes it has the ability to reliably estimate returns and therefore recognizes revenue on the sale of DUEXIS, RAYOS and VIMOVO at the point of sale to the wholesaler.
	Product Sales Discounts and Allowances
	Prior to the fourth quarter of 2012, the Company recorded DUEXIS sales to wholesale pharmaceutical distributors and retail chains as deferred revenue. Allowances for product returns, rebates and discounts were also deferred at the time of sale to wholesale pharmaceutical distributors and national and regional retail chains. These deferred expenses were recognized to arrive at net product sales at the time the related revenue was recognized. In the fourth quarter of 2012, the Company began recognizing revenue at the point of sale to its wholesale pharmaceutical distributors and retail chains, at which point the associated allowances for product returns, rebates and allowances were also recognized. The Company is required to make significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the Company will be required to make adjustments to these allowances in the future. In connection with its marketing of VIMOVO in the United States, the Company has been recognizing VIMOVO revenue at the point of sale to its wholesale pharmaceutical distributors and retail chains.
	Customer Discounts and Rebates
	Product Launch Discounts
	The Company has offered additional discounts to wholesale distributors for product purchased at the time of product launch. The Company has recorded these discounts as an allowance against accounts receivable and a reduction of revenue when orders were placed.
	Customer Rebates
	The Company participates in certain commercial rebate programs. Under these rebate programs, the Company pays a rebate to the commercial entity or third-party administrator of the program. The Company accrues estimated rebates based on contract prices, estimated percentages of product sold to qualified patients and estimated levels of inventory in the distribution channel and records the rebate as a reduction of revenue.
	Distribution Service Fees
	The Company includes distribution service fees paid to its wholesalers for distribution and inventory management services as a reduction to revenue. The estimates are based on contractually determined fees, typically as a percentage of revenue.
	Government Rebates and Chargebacks
	Government Rebates
	The Company participates in certain federal government rebate programs, such as Medicare and Medicaid. The Company accrues estimated rebates based on percentages of product sold to qualified patients, estimated rebate percentages and estimated levels of inventory in the distribution channel that will be sold to qualified patients and records the rebate as a reduction of revenue.
	Government Chargebacks
	The Company provides discounts to federal government qualified entities with whom the Company has contracted. These federal entities purchase products from the wholesale pharmaceutical distributors at a discounted price, and the wholesale pharmaceutical distributors then charge back to the Company the difference between the current retail price and the contracted price that the federal entities paid for the products. The Company accrues estimated chargebacks based on contract prices and sell-through sales data obtained from third party information and records the chargeback as a reduction of revenue.
	Co-Pay Assistance
	The Company offers discount card programs to patients under which the patient receives a discount on his or her prescription. The Company reimburses pharmacies for this discount through a third-party vendor. The Company records the total amount of estimated discounts for sales recorded in the period as a reduction of revenue.
	Returns and Prompt Pay Allowances
	Sales Returns
	Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the product expiration date. Generally, product may be returned for a period beginning six months prior to its expiration date and up to one year after its expiration date. The right of return expires on the earlier of one year after the product expiration date or the time that the product is dispensed to the patient. The majority of product returns result from product dating, which falls within the range set by the Company’s policy, and are settled through the issuance of a credit to the customer. The estimate of the provision for returns is based upon the Company’s historical experience with actual returns, which is applied to the level of sales for the period that corresponds to the period during which the customer may return product. This period is known to the Company based on the shelf life of products at the time of shipment. The Company records sales returns as an allowance against accounts receivable and a reduction of revenue.
	Prompt Pay Discounts
	As an incentive for prompt payment, the Company offers a 2% cash discount to customers. The Company expects that all customers will comply with the contractual terms to earn the discount. The Company records the discount as an allowance against accounts receivable and a reduction of revenue.
	Bad Debt Expense
	The Company’s products are sold to wholesale distributors and retail chains through manufacturing and supply agreements. For the years ended December 31, 2013, 2012 and 2011, the Company did not experience a bad debt expense related to its accounts receivable balances. Accordingly, the Company has not established a reserve for bad debt expense. The Company will continue to monitor its accounts receivable balances to determine the impact, if any, of such factors as changes in customer concentration, credit risk and the realizability of its accounts receivable would require a bad debt reserve allowance in subsequent periods.
	Cost of Goods Sold
	The Company recognizes cost of goods sold in connection with its sale of DUEXIS and RAYOS.
	Cost of goods sold of DUEXIS includes all costs directly related to the acquisition of product from the Company’s third party manufacturers, including freight charges and costs of distribution.
	Cost of goods sold of RAYOS includes all costs directly related to the acquisition of product from the Company’s third party manufacturers, including freight charges, amortization of developed technology, royalty payments to third parties for the use of certain licensed patents and applicable taxes.
	Until the Company began recognizing revenue at the point of sale of DUEXIS to the wholesaler in the fourth quarter of 2012, it also deferred the related DUEXIS cost of goods sold and recorded such amounts as other current assets until revenue was recognized.
	Cost of goods sold of LODOTRA includes raw material costs, costs associated with third parties who manufacture LODOTRA for the Company, supply chain costs, manufacturing overhead costs, amortization of developed technology, royalty payments to third parties for the use of certain licensed patents and applicable taxes.
	Cost of goods sold for VIMOVO in the fourth quarter of 2013, following our acquisition in November 2013 of certain assets and rights necessary to commercialize VIMOVO in the United States, includes only intangible amortization expense. Beginning in 2014, in connection with the Company’s marketing of VIMOVO in the United States, cost of goods sold for VIMOVO will include all costs directly related to the acquisition of product from AstraZeneca and/or the third-party manufacturer.
	Inventories
	Inventories are stated at the lower of cost or market value. Inventories consist of raw materials, work-in-process and finished goods. The Company has entered into manufacturing and supply agreements for the manufacture or purchase of raw materials and production supplies. The Company’s inventories include the direct purchase cost of materials and supplies and manufacturing overhead costs. As of December 31, 2013 and December 31, 2012, the Company had inventories of $8,701 and $5,245, respectively.
	Inventories exclude product sample inventory, which is included in other current assets and is expensed as a component of sales and marketing expense when provided to physicians or healthcare providers. As of December 31, 2013 and 2012, the Company had product sample inventory of $1,323 and $875, respectively.
	Preclinical Studies and Clinical Trial Accruals
	The Company’s preclinical studies and clinical trials have historically been conducted by third-party contract research organizations and other vendors. Preclinical study and clinical trial expenses are based on the services received from these contract research organizations and vendors. Payments depend on factors such as the milestones accomplished, successful enrollment of certain numbers of patients and site initiation. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly. To date, the Company has had no significant adjustments to accrued clinical expenses.
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. For the periods presented, the Company’s potential dilutive shares, which include shares issuable upon the exercise of outstanding stock options, unvested restricted stock units and warrants to purchase common stock, have not been included in the computation of diluted net loss per share for the periods presented in which there is a net loss as the result would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share.
	Cash and Cash Equivalents
Cash and cash equivalents primarily consist of cash balances and money market funds. Cash and cash equivalents were $80,480 and $104,087 as of December 31, 2013 and 2012, respectively. The Company’s policy is to invest excess cash in money market funds, which are generally of a short-term duration based upon operating requirements.
Restricted Cash
Restricted cash consists of balances included in interest-bearing money market accounts required by a vendor for the Company’s sponsored employee credit card program and by the lessor for the Company’s corporate office. As of December 31, 2013 and 2012, the Company had restricted cash in the amount of $738 and $800, respectively.
Fair Value of Financial Instruments
The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The estimated fair value of the Company’s derivative liability related to the convertible portion of its 5.00% Convertible Senior Notes due 2018 (the “Convertible Senior Notes”) was derived utilizing the binomial lattice approach for the valuation of convertible instruments. Assumptions used in the calculation included, among others, determining the appropriate credit spread using benchmarking analysis and solving for the implied credit spread, calculating the fair value of the stock component using a discounted risk free rate and borrowing cost and calculating the fair value of the note component using a discounted credit adjusted discount rate. Based on the assumptions used to determine the fair value of the derivative liability associated with the Convertible Senior Notes, the Company concluded that these inputs were Level 3 inputs. The Company will continue to derive the fair value of the derivative liability using the binomial lattice approach and these assumptions in all future reporting periods.
Business Combinations
The Company accounts for business combinations in accordance with the pronouncement guidance in ASC 805, Business Combinations, in which acquired assets and liabilities are measured at their respective estimated fair values as of the acquisition date. The Company may be required, as in the case of intangible assets, contingent royalties or derivatives, to determine the fair value associated with these amounts by estimating the fair value using an income approach under the discounted cash flow method, which may include revenue projections and other assumptions made by the Company to determine the fair value.
Property and Equipment, Net
Property and equipment are stated at cost less accumulated depreciation. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets for financial reporting purposes and an accelerated method for income tax reporting purposes. Upon retirement or sale of an asset, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repair and maintenance costs are charged to expenses as incurred and improvements are capitalized.
Leasehold improvements are amortized on a straight-line basis over the term of the applicable lease, or the useful life of the assets, whichever is shorter.
Depreciation and amortization periods for the Company’s property and equipment are as follows:
Machinery and equipment	5-7 years
Furniture and fixtures	3-5 years
Computer equipment	3 years
Software	3 years
Trade show equipment	3 years
Software includes internal-use software acquired and modified to meet the Company’s internal requirements. Amortization commences when the software is ready for its intended use.
Intangible Assets
The Company’s intangible assets consist of developed technology related to three of its approved products: LODOTRA outside the United States, RAYOS in the United States and intellectual property rights related to the Company’s acquisition of the U.S. rights to VIMOVO. The Company amortizes the LODOTRA and RAYOS intangible assets over twelve years, which is the estimated useful life of the underlying patents, and amortizes the U.S. intellectual property rights of the VIMOVO intangible asset over an estimated useful life of 61.5 months. The Company reviews its intangible assets when events or circumstances may indicate that the carrying value of these assets exceeds their fair value. The Company measures fair value based on the estimated future discounted cash flows associated with these assets in addition to other assumptions and projections that the Company deems to be reasonable and supportable.
Research and Development Expenses
Research and development expenses include, but are not limited to, payroll and other personnel expenses, consultant expenses, expenses incurred under agreements with contract research organizations to conduct clinical trials and expenses incurred to manufacture clinical trial materials.
Sales and Marketing Expenses
Sales and marketing expenses consist principally of payroll of sales representatives and marketing and support staff, travel and other personnel-related expenses, marketing materials and distributed sample inventories. With the full commercial launch of RAYOS in the United States in late January 2013, the Company determined that costs related to medical affairs, which consist of expenses related to scientific publications, health outcomes, biostatistics, medical education and information, and medical communications, should be charged to sales and marketing expenses as incurred in accordance with GAAP. Prior to the full commercial launch of RAYOS, these medical affairs expenses were classified as research and development expenses.
Concentration of Credit Risk and Other Risks and Uncertainties
Financial instruments that may potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. The Company’s cash and cash equivalents are invested in deposits with various banks in the United States, Switzerland and Germany that management believes are creditworthy. At times, deposits in these banks may exceed the amount of insurance provided on such deposits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents.
The Company’s LODOTRA sales contracts are principally denominated in Euros and, therefore, its revenues are subject to significant foreign currency risk.
To achieve profitable operations, the Company must successfully develop, obtain regulatory approval for, manufacture and market its products and product candidates, and/or acquire or in-license products from third parties. There can be no assurance that any additional products can be developed, will be approved for marketing by the regulatory authorities, or can be manufactured at an acceptable cost and with appropriate performance characteristics or that any new or existing products can be successfully marketed, acquired or in-licensed by the Company. These factors could have a material adverse effect on the Company’s operations.
The Company relies on third parties to manufacture its commercial supplies of DUEXIS, VIMOVO and RAYOS/LODOTRA. The commercialization of any of its products or product candidates could be stopped, delayed or made less profitable if those third parties fail to provide the Company with sufficient quantities of product or fail to do so at acceptable quality levels or prices.
The Company is required to maintain compliance with applicable Swiss laws with respect to its Swiss subsidiary, Horizon Pharma AG, including laws requiring maintenance of equity in the subsidiary to avoid overindebtedness, which requires Horizon Pharma AG to maintain assets in excess of its liabilities. The Company reviews on a regular basis whether its Swiss subsidiary is overindebted. As of December 31, 2013 and 2012, the Company’s Swiss subsidiary was overindebted, primarily as a result of operating losses at the subsidiary. The Company will continue to monitor and review steps to address any overindebtedness until such time as its Swiss subsidiary may generate positive income at a statutory level, which could require the Company to have cash at its Swiss subsidiary in excess of its near term operating needs and could affect the Company’s ability to have sufficient cash at its U.S. subsidiary to meet its near term operating needs. As of December 31, 2013 and 2012, Horizon Pharma AG had cash and cash equivalents of $3,476 and $4,708, respectively. Based upon the cash and cash equivalents held by Horizon Pharma AG as of December 31, 2013 and 2012 and Horizon Pharma AG’s level of overindebtedness at such time, the Company does not expect that its financial position or results of operations will be materially affected by any need to address overindebtedness at its Swiss subsidiary. To date, the overindebtedness of the Company’s Swiss subsidiary has not resulted in the need to divert material cash resources from its U.S. subsidiary.
Historically, the Company’s accounts receivable balances have been highly concentrated with a select number of customers, consisting primarily of large wholesale pharmaceutical distributors who, in turn, sell the products to pharmacies, hospitals and other customers. For the year ended December 31, 2013, the Company’s top five customers, AmerisourceBergen, McKesson Corporation, Cardinal Health, Inc., Mundipharma and Rochester Drug Company, accounted for approximately 89% of total consolidated gross sales. For the year ended December 31, 2012, the Company’s top three customers, Mundipharma, McKesson Corporation and Cardinal Health, Inc., accounted for approximately 83% of total consolidated gross sales. In addition, four customers, McKesson Corporation, AmerisourceBergen, Rochester Drug Company and Cardinal Health, Inc., accounted for approximately 85% of the Company’s total outstanding accounts receivable balances at December 31, 2013. As of December 31, 2012, three customers, Cardinal Health, Inc., Walgreen Company and McKesson Corporation, accounted for approximately 77% of the Company’s total outstanding accounts receivable balances. Historically, the Company has not experienced any losses related to its accounts receivable balances.
Comprehensive Income (Loss)
Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss) (“OCI”). OCI includes certain changes in stockholders’ equity that are excluded from net income (loss), which consist of foreign currency translation adjustments. In February 2013, the Company adopted on a prospective basis FASB Accounting Standards Update 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). ASU 2013-02 requires an entity to report the effect of significant reclassifications out of accumulated OCI on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. As of December 31, 2013 and 2012, accumulated other comprehensive loss was $2,403 and $3,372, respectively.

Business_Acquisition

Business Acquisition	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Business Acquisition	'
	NOTE 3 – BUSINESS ACQUISITION
	On November 18, 2013, the Company entered into agreements with AstraZeneca pursuant to which the Company acquired from AstraZeneca and its affiliates certain intellectual property and other assets, and assumed from AstraZeneca and its affiliates certain liabilities, each with respect to VIMOVO, and obtained rights to develop other pharmaceutical products that contain gastroprotective agents in a single fixed combination oral solid dosage form with NSAIDs, in the United States. VIMOVO (naproxen/esomeprazole magnesium), a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a proton pump inhibitor, layer surrounding the core, was approved by the FDA in 2010 for the relief of the signs and symptoms of OA, RA and AS, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.
	Pursuant to the transactions contemplated by the asset purchase agreement, the Company acquired certain existing assets and rights necessary to commercialize VIMOVO in the United States including, among other things, the IND and NDA for VIMOVO in the United States, AstraZeneca’s interest in certain patents covering VIMOVO in the United States and certain promotional materials and records related to VIMOVO in the United States. The Company will also be entitled to the benefit of a covenant not to sue granted by Merck Sharp & Dohme Corp. and certain of its affiliates (collectively, “Merck”) to AstraZeneca, with respect to certain patents owned by AstraZeneca but exclusively licensed to Merck, that cover the manufacture and commercialization of VIMOVO in the United States. In addition, AstraZeneca assigned to the Company its amended and restated collaboration and license agreement for the United States with Pozen pursuant to which AstraZeneca has in-licensed from Pozen certain patents and know-how of Pozen covering VIMOVO in the United States. The terms of the amended and restated collaboration and license agreement for the United States with Pozen (the “Pozen license agreement”) are described below.
	In November 2013, in connection with the closing of the transactions contemplated by the asset purchase agreement, the Company also entered into a license agreement with AstraZeneca, a supply agreement with AstraZeneca’s affiliate, AstraZeneca LP, and certain other agreements that are described below. The Company also executed a transition agreement with AstraZeneca pursuant to which AstraZeneca transitioned to the Company regulatory and commercial responsibility for VIMOVO in the United States. From the closing of the transaction until December 31, 2013, AstraZeneca continued to commercialize VIMOVO in the United States under AstraZeneca’s existing pricing and paid to the Company the net profits recognized on sales of VIMOVO in the United States. Beginning January 1, 2014, the Company commenced commercialization of VIMOVO in the United States on its own behalf and under new pricing for VIMOVO. In consideration for the U.S. rights to VIMOVO, the Company paid to AstraZeneca a one-time upfront cash payment of $35,000.
	The Company is responsible for and controls matters relating to VIMOVO in the United States, including responsibility for commercialization of VIMOVO in the United States, responsibility for ongoing developmental and regulatory activities with respect to VIMOVO in the United States and responsibility for the current VIMOVO litigation with respect to the patents the Company purchased under the asset purchase agreement and the patents the Company licensed from Pozen under the Pozen license agreement. AstraZeneca will be responsible for and will retain control of VIMOVO outside the United States.
	Additionally, in connection with the closing of the transactions contemplated by the asset purchase agreement, the Company entered into a license agreement with AstraZeneca (the “AstraZeneca license agreement”), pursuant to which AstraZeneca granted the Company an exclusive license under certain intellectual property (including patents, know-how, trademarks, copyrights and domain names) of AstraZeneca and its affiliates to develop, manufacture and commercialize VIMOVO in the United States. AstraZeneca also granted the Company a non-exclusive license under certain intellectual property of AstraZeneca and its affiliates to manufacture, import, export and perform research and development activities with respect to VIMOVO outside the United States but solely for purposes of commercializing VIMOVO in the United States. In addition, AstraZeneca granted the Company a non-exclusive right of reference and use under certain regulatory documentation controlled by AstraZeneca and its affiliates to develop, manufacture and commercialize VIMOVO in the United States and to manufacture, import, export and perform research and development activities with respect to VIMOVO outside the United States but solely for purposes of commercializing VIMOVO in the United States.
	Under the AstraZeneca license agreement, the Company granted AstraZeneca a non-exclusive sublicense under such licensed intellectual property and a non-exclusive right of reference under certain regulatory documentation controlled by the Company to manufacture, import, export and perform research and development activities with respect to VIMOVO in the United States but solely for purposes of commercializing VIMOVO outside the United States.
	Under the AstraZeneca license agreement, the Company and its affiliates are subject to certain limitations and restrictions on its ability to develop, commercialize and seek regulatory approval with respect to VIMOVO or other products that contain gastroprotective agents in a single fixed combination oral solid dosage form with NSAIDs (excluding DUEXIS). These limitations and restrictions include, among other things, restrictions on indications for which the Company may commercialize VIMOVO or any such other products, restrictions on the Company’s ability to develop or seek regulatory approval with respect to such other products that contain esomeprazole, restrictions on the Company’s ability to develop or seek regulatory approval for VIMOVO for any indications other than the indications for which NSAIDs are indicated, and restrictions on the Company’s marketing activities with respect to VIMOVO and any such other products.
	Under the Pozen license agreement, Pozen granted to the Company an exclusive, royalty-bearing license under certain of Pozen’s intellectual property in the United States to manufacture, develop and commercialize VIMOVO and other products controlled by the Company that contain gastroprotective agents in a single fixed combination oral solid dosage form with NSAIDs, excluding DUEXIS, in the United States.
	Under the Pozen license agreement, the Company is required to pay Pozen a flat 10% royalty on net sales of VIMOVO and such other products sold by the Company, its affiliates or sublicensees during the royalty term, subject to minimum annual royalty obligations of $5.0 million in 2014 and $7.5 million each year thereafter, which minimum royalty obligations will continue for each year during which one of Pozen’s patents covers such products in the United States and there are no competing products in the United States. The royalty rate may be reduced to a mid-single digit royalty rate as a result of loss of market share to competing products. The Company’s obligation to pay royalties to Pozen will expire upon the later of (a) expiration of the last-to-expire of certain patents covering such products in the United States, and (b) ten years after the first commercial sale of such products in the United States. In addition, the Company is obligated to reimburse Pozen for costs, including attorneys’ fees, incurred by Pozen in connection with VIMOVO patent litigation moving forward, subject to agreed caps.
	The Company is responsible for and is required to use diligent and reasonable efforts to commercialize VIMOVO or another qualified product in the United States. The Company also owns and maintains all regulatory filings and marketing approvals in the United States for any such products, including all INDs and NDAs for VIMOVO. Pozen has covenanted that it will not at any time prior to the expiration of the royalty term, and will ensure that its affiliates do not, directly or indirectly, develop or commercialize or license any third party to develop or commercialize certain competing products in the United States.
	The Pozen license agreement, unless earlier terminated, will expire upon expiration of the royalty term for all such products in the United States. Either party has the right to terminate the agreement upon any uncured material breach by the other party or upon the bankruptcy or similar proceeding of the other party. The Company also has the right to terminate the Pozen license agreement for cause upon certain defined product failures.
	In November 2013, in connection with the asset purchase agreement and the Pozen license agreement, the Company, AstraZeneca and Pozen entered into a letter agreement in which Pozen consented to AstraZeneca’s assignment of the Pozen license agreement to the Company and that addresses the rights and responsibilities of the parties in relation to the Pozen license agreement and the amended and restated collaboration and license agreement between Pozen and AstraZeneca for territories outside the United States (the “Pozen-AstraZeneca license agreement”). Under the letter agreement, the Company and AstraZeneca agreed to pay Pozen milestone payments upon the achievement by the Company and AstraZeneca, collectively, of certain annual aggregate global sales thresholds ranging from $550.0 million to $1.25 billion with respect to products licensed by Pozen to the Company under the Pozen license agreement and to AstraZeneca under the Pozen-AstraZeneca license agreement. The aggregate milestone payment amount that may be owed by AstraZeneca and the Company, collectively, under the letter agreement is $260.0 million, with the amount payable by each of the Company and AstraZeneca with respect to each milestone to be based upon the proportional sales achieved by each of the Company and AstraZeneca, respectively, in the applicable year.
	The letter agreement will terminate with respect to Pozen and the Company upon the termination of the Pozen license agreement and will terminate with respect to Pozen and AstraZeneca upon the termination of the Pozen-AstraZeneca license agreement.
	In November 2013, in connection with the asset purchase agreement, the Company entered into a supply agreement with AstraZeneca pursuant to which AstraZeneca agreed to supply VIMOVO to the Company for commercialization in the United States through December 31, 2014. Under the supply agreement, AstraZeneca will supply the quantity of VIMOVO that the Company orders, both for the Company’s own use and for use by the Company’s sublicensees, on a transitional basis through December 31, 2014. The Company agreed to pay a set transfer price agreed to by the Company and AstraZeneca for quantities of VIMOVO supplied by AstraZeneca under the supply agreement.
	The supply agreement will expire on December 31, 2014, unless terminated earlier as described herein. The supply agreement may be terminated earlier by either party for any uncured material breach by the other party of its obligations under the supply agreement or upon the bankruptcy or similar proceeding of the other party. Additionally, the Company has the right to terminate the supply agreement at any time upon 120 days prior written notice to AstraZeneca or immediately upon written notice if the existing regulatory approval of VIMOVO is suspended for any reason or if any regulatory authority provides a warning letter or other official documentation expressing major and significant concerns from a regulatory perspective with AstraZeneca’s or its affiliates’ or third party manufacturer’s manufacturing of VIMOVO. Additionally, the supply agreement will automatically terminate upon any termination of the AstraZeneca license agreement.
	Pursuant to ASC Topic 805, Business Combinations, the Company accounted for the acquisition of the U.S. rights to VIMOVO under the acquisition method of accounting, in which the Company recognized and accounted for the acquisition of the U.S. rights to VIMOVO as a business combination. Net tangible and intangible assets acquired and contingent royalty liabilities, based upon their respective estimated fair values as of the acquisition date (November 22, 2013). The following table shows the fair values assigned to the assets acquired and liabilities assumed by the Company as part of the asset purchase agreement:
		Allocation
	Samples inventory	$	287
	VIMOVO intellectual property		67,705
	Contingent royalty liabilities		(32,992	)
	Total cash consideration paid	$	35,000
	The valuation of the intellectual property acquired, an identifiable intangible asset, was based on management’s estimates, information and reasonable and supportable assumptions. The allocation was generally based on the Company’s estimated fair value of the rights to payments with respect to U.S. revenue associated with VIMOVO which were acquired in the transaction. This estimated fair value was determined using the income approach under the discounted cash flow method. Significant assumptions used in valuing the intellectual property intangible asset included revenue projections through 2030 based on assumptions relating to pricing and reimbursement rates and market size and market penetration rates, cost of goods sold based on current manufacturing experience, general and administrative expenses, sales and marketing expenses, and research and development expenses for clinical and regulatory support. The calculated value of the VIMOVO intellectual property intangible asset is amortized using the straight-line method over an estimated useful life of 61.5 months.
	Additionally, the Company assigned a fair value to its liability for contingent royalties. The contingent royalty liability was based on anticipated revenue streams utilizing the income approach under the discounted cash flow method. As a result, the Company recorded $33,000 of fair value royalty payments due to Pozen, of which $24,500 was guaranteed during the years 2014 through 2018 and $8,500 was contingent on meeting certain revenue targets.
	Pro Forma Financial Information
	The following table represents the consolidated financial information for the Company on a pro forma basis, assuming that the acquisition of the U.S. rights to VIMOVO occurred as of January 1, 2012. The historical financial information has been adjusted to give effect to pro forma items that are directly attributable to the acquisition and are expected to have a continuing impact on the consolidated results. These items include, among others, adjustments to record the amortization of acquired VIMOVO intellectual property and interest expense, debt discount and deferred financing costs associated with the convertible debt issued in connection with the acquisition. Additionally, the following table sets forth unaudited financial information and has been compiled from historical financial statements and other information, but is not necessarily indicative of the results that actually would have been achieved had the transactions occurred on the dates indicated or that may be achieved in the future.
		For the Years Ended December 31,
		2013								2012
		As reported			Pro-forma		Pro-forma			As			Pro-forma			Pro-forma
					adjustments		(Unaudited)			reported			adjustments			(Unaudited)
					(Unaudited)								(Unaudited)
	Net revenues	$	74,016		$	20,379	$	94,395		$	18,844		$	25,195		$	44,039
	Net income (loss)		(149,005	)		14,464		(134,541	)		(87,794	)		(38,793	)		(126,587	)
	Loss per share: Basic and diluted	$	(2.34	)	$	0.23	$	(2.11	)	$	(2.26	)	$	(1.00	)	$	(3.26	)

Earnings_per_Share

Earnings per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings per Share	'
	NOTE 4 – EARNINGS PER SHARE
	The following table presents basic and diluted earnings (loss) per share for the years ended December 31, 2013, 2012 and 2011 as follows:
			For the Years Ended December 31,
			2013			2012			2011
	Basic and diluted earnings per share calculation:
	Net loss		$	(149,005	)	$	(87,794	)	$	(113,265	)
	Weighted average of common shares outstanding			63,657,924			38,871,422			9,014,968
	Basic and diluted net loss per share		$	(2.34	)	$	(2.26	)	$	(12.56	)
	The following securities were excluded from the computation of diluted earnings per share for the years ended December 31, 2013, 2012 and 2011 due to the anti-dilutive effects resulting from the Company’s net loss for the periods presented:
		•		Outstanding stock options to purchase an aggregate of 4,411,080, 2,746,918 and 2,532,262 shares of common stock at December 31, 2013, 2012 and 2011, respectively; outstanding and unvested restricted stock units covering an aggregate of 833,001, 232,158 and 304,890 shares of common stock at December 31, 2013, 2012 and 2011, respectively; and 101,004 and 225,000 vested restricted stock units outstanding at December 31, 2013 and 2012, respectively.
		•		Outstanding common stock warrants to purchase an aggregate of 16,114,746 and 17,480,243 shares of common stock at December 31, 2013, and 2012, respectively.
		•		The conversion of approximately 13,164,951 shares of the Company’s common stock associated with the conversion feature of the Convertible Senior Notes as the conversion of the Convertible Senior Notes is subject to receiving stockholder approval to issue enough authorized and unissued shares to cover the conversion option and satisfy the NASDAQ share cap rule.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	NOTE 5 – INVENTORIES
	Inventories are stated at the lower of cost or market value. Inventories consist of raw materials, work-in-process and finished goods. The Company has entered into manufacturing and supply agreements for the manufacture or purchase of raw materials and production supplies. The Company’s inventories include the direct purchase cost of materials and supplies and manufacturing overhead costs. Inventories exclude product sample inventory, which are included in other current assets and are expensed as a component of sales and marketing expense when provided to physicians or healthcare providers.
	The components of inventories as of December 31, 2013 and 2012 consisted of the following:
		As of December 31,
		2013		2012
	Raw materials	$	91	$	40
	Work-in-process		522		824
	Finished goods		8,088		4,381
	Net inventories	$	8,701	$	5,245

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Prepaid Expenses and Other Current Assets	'
	NOTE 6 – PREPAID EXPENSES AND OTHER CURRENT ASSETS
	Prepaid expenses and other current assets as of December 31, 2013 and 2012 consisted of the following:
		As of December 31,
		2013		2012
	Product samples inventory	$	1,323	$	875
	Prepaid software license fees		855		—
	Prepaid clinical trial studies		688		661
	Prepaid co-pay expenses		621		—
	Prepaid marketing expenses		381		607
	Prepaid insurance		379		265
	Prepaid FDA product and manufacturing fees		312		139
	Other prepaid expenses		329		745
	Other current assets		—		31
	Total prepaid and other current assets	$	4,888	$	3,323

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	NOTE 7 – PROPERTY AND EQUIPMENT
	Property and equipment as of December 31, 2013 and 2012 consisted of the following:
		As of December 31,
		2013			2012
	Machinery and equipment	$	2,367		$	2,248
	Furniture and fixtures		113			116
	Computer equipment		2,160			1,211
	Software		775			646
	Trade show equipment		228			228
	Leasehold improvement		783			783
			6,426			5,232
	Less-accumulated depreciation		(2,646	)		(1,507	)
	Total property and equipment	$	3,780		$	3,725
	Depreciation expense for the years ended December 31, 2013, 2012 and 2011 was $1,173, $806 and $446, respectively.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	NOTE 8 – INTANGIBLE ASSETS
	The Company’s intangible assets consist of developed technology related to the Company’s approved products: LODOTRA in Europe, RAYOS in the United States, and VIMOVO intellectual property rights in the United States.
	On July 26, 2012, the FDA approved RAYOS for the treatment of a broad range of indications, which resulted in the Company reclassifying the entire asset balance of $35,456 from its indefinite-lived in-process research and development (“IPR&D”) asset to a finite-lived developed technology asset and commenced amortization. At December 31, 2012, the Company had no remaining IPR&D intangible assets.
	On November 18, 2013, the Company entered into an asset purchase agreement with AstraZeneca, pursuant to which the Company acquired from AstraZeneca and its affiliates certain intellectual property with respect to VIMOVO and obtained the rights to develop other pharmaceutical products that contain gastroprotective agents in a single fixed combination oral solid dosage form with NSAIDs in the United States.
	The Company tests its intangible assets for impairment when events or circumstances may indicate that the carrying value of these assets exceeds their fair value. During the fourth quarter of 2011, the Company performed its annual test of its indefinite-lived intangible assets for impairment. The Company utilized a fair value approach by calculating its business enterprise value, which equated to the market value of the Company’s common stock as of December 31, 2011, and included an appropriate control risk premium. The result of this analysis indicated that the carrying value of its IPR&D asset was impaired. Additionally, the Company calculated the business enterprise value, which included its IPR&D asset, using a discounted cash flow approach. The fair value of the IPR&D utilizing this method was estimated to be $36,638 as of December 31, 2011. Accordingly, the Company recorded an intangible impairment charge related to its IPR&D asset of $69,621 during the fourth quarter of 2011. The Company does not believe there have been any circumstances or indicators that carrying value of any of its intangible assets has been impaired as of December 31, 2013.
	In connection with the reclassification of IPR&D to developed technology in the third quarter of 2012, the Company conducted a fair value assessment related to the carrying value of this asset. The analysis indicated that the fair value of the developed technology asset exceeded its carrying value, which resulted in no impairment. Developed technology associated with the Company’s approved and/or marketed products is amortized on a straight-line basis over its estimated useful life of twelve years for both RAYOS and LODOTRA.
	As of December 31, 2013 and 2012, intangible assets consisted of the following:
		December 31, 2013										December 31, 2012
		Cost		Accumulated			Currency			Net Book		Cost		Accumulated			Currency			Net Book
		Basis		Amortization			Translation			Value		Basis		Amortization			Translation			Value
	Developed technology	$	84,779	$	(17,823	)	$	(2,136	)	$	64,820	$	84,779	$	(11,118	)	$	(4,769	)	$	68,892
	VIMOVO intellectual property		67,705		(1,431	)		—			66,274		—		—			—			—
	Total intangible assets	$	152,484	$	(19,254	)	$	(2,136	)	$	131,094	$	84,779	$	(11,118	)	$	(4,769	)	$	68,892
	Amortization expense of the Company’s developed technology for the years ended December 31, 2013, 2012 and 2011 was $8,137, $4,732 and $3,753, respectively. As of December 31, 2013, estimated future amortization expense was as follows:
	2014	$	19,906
	2015		19,906
	2016		19,906
	2017		19,906
	2018 and thereafter		51,471
	Total	$	131,094

Other_Assets

Other Assets	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Other Assets	'
	NOTE 9 – OTHER ASSETS
	Other assets as of December 31, 2013 and 2012, consisted of the following:
		As of December 31,
		2013		2012
	Deferred financing costs	$	6,268	$	3,195
	Long-term clinical study deposits		114		661
	Long-term inventory deposits		479		505
	Other		96		88
	Total other assets	$	6,957	$	4,449

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Accrued Liabilities	'
	NOTE 10 – ACCRUED LIABILITIES
	Accrued liabilities as of December 31, 2013 and 2012, consisted of the following:
		As of December 31,
		2013		2012
	Payroll related expenses	$	9,491	$	6,290
	Accrued trade discounts and rebates		8,463		2,704
	Sales and marketing expenses		1,761		1,265
	Accrued interest		810		2,538
	Deferred rent		755		876
	Clinical and regulatory expenses		488		652
	Professional services		350		399
	Contract manufacturing expenses		301		1,094
	Consulting services		283		228
	Accrued other		1,347		738
	Total accrued liabilities	$	24,049	$	16,784

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	NOTE 11 – FAIR VALUE MEASUREMENTS
	The following tables set forth the Company’s financial instruments that are measured at fair value on a recurring basis within the fair value hierarchy. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1 - Observable inputs such as quoted prices in active markets for identical assets or liabilities.
	Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company utilizes the market approach to measure fair value for its money market funds. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
	Assets and liabilities measured at fair value on a recurring basis
	The following table sets forth the Company’s financial assets and liabilities at fair value on a recurring basis as of December 31, 2013 and 2012:
		2013
		Level 1			Level 2			Level 3		Total
	Assets:
	Money market funds	$	66,817		$	—		$	—	$	66,817
	Total assets at fair value	$	66,817		$	—		$	—	$	66,817
	Liabilities:
	Derivative liability	$	—		$	—		$	109,410	$	109,410
	Total liabilities at fair value	$	—		$	—		$	109,410	$	109,410
		2012
		Level 1			Level 2			Level 3		Total
	Assets:
	Money market funds	$	97,670		$	—		$	—	$	97,670
	Total assets at fair value	$	97,670		$	—		$	—	$	97,670
	In accordance with the pronouncement guidance in ASC 815 “Derivatives and Hedging”, the conversion option included within the Convertible Senior Notes was deemed to include an embedded derivative, which required the Company to bifurcate and separately account for the embedded derivative as a separate liability on its consolidated balance sheets. The estimated fair value was derived utilizing the binomial lattice approach for the valuation of convertible instruments. Assumptions used in the calculation included, among others, determining the appropriate credit spread using benchmarking analysis and solving for the implied credit spread, calculating the fair value of the stock component using a discounted risk free rate and borrowing cost and calculating the fair value of the note component using a discounted credit adjusted discount rate. Based on the assumptions used to determine the fair value of the derivative liability associated with the Convertible Senior Notes, the Company concluded that these inputs were Level 3 inputs.
	The following table presents the assumptions used by the Company to determine the initial fair value and the fair value as of December 31, 2013 of the conversion option embedded in the Convertible Senior Notes:
		November 18,			December 31,
		2013			2013
	Stock price	$	4.47		$	7.62
	Risk free rate		1.33	%		1.69	%
	Borrowing cost		5.0% and 3.5	%		5.0% and 3.5	%
	Weights		Equal weight			Equal weight
	Credit spread (in basis points)		1,030 and 1,170			930 and 1,170
	Volatility		40	%		40	%
	Initial conversion price	$	5.36		$	5.36
	Remaining time to maturity (in years)		5			4.9
	As part of the Company’s accounting entries to record the Convertible Senior Notes, the Company recorded a $40,110 derivative liability. At December 31, 2013, the Company conducted a fair value assessment to properly reflect the market value adjustments for the embedded derivative due to changes in the Company’s common stock value. To properly reflect the fair value of the embedded derivative of $109,410 as of December 31, 2013, the Company recorded a $69,300 expense in its results of operations for the three and twelve months ended December 31, 2013.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	NOTE 12 – COMMITMENTS AND CONTINGENCIES
	Lease Obligations
	In September 2011, the Company entered into an office lease agreement for 21,182 square feet of office space in Deerfield, Illinois, which was effective August 31, 2011. The initial term of the lease commenced on December 1, 2011, and expires on June 30, 2018. The minimum net rent was initially approximately $30 per month during the first year and increases each year during the initial term, up to approximately $35 per month after the sixth year. The Company has the option to extend the lease for an additional five-year term, which would commence upon the expiration of the initial term. In August 2012, the Company entered into an amendment to the lease agreement to expand the office space available to it by an additional 4,926 square feet in the same Deerfield, Illinois facility as its existing office space. The initial rent on the additional lease is $7 per month and will increase up to a maximum of $8 per month after the sixth year. In December 2013, the Company entered into a second amendment to the lease agreement to expand the office space available to it by an additional 8,352 square feet. The two amendments to the lease term coincide with the original lease and run through June 30, 2018. The initial rent on the second amendment is $12 per month and will increase up to a maximum of $14 per month after the fifth year.
	The Company also leases its offices in Reinach, Switzerland and in Mannheim, Germany. The Reinach office lease rate is $7 (6 CHF) per month, expiring on May 31, 2015. The Mannheim office lease rate is approximately $7 (5 Euros) per month, expiring on December 31, 2014.
	The Company recognizes rent expense on a monthly basis over the lease term based on a straight-line method. Rent expense was $463, $458 and $507 for the years ended December 31, 2013, 2012 and 2011, respectively.
	Annual Purchase Commitments
	In August 2007, the Company entered into a manufacturing and supply agreement with Jagotec AG (“Jagotec”). Under the agreement, Jagotec or its affiliates are required to manufacture and supply RAYOS/LODOTRA exclusively to the Company in bulk. The Company committed to a minimum purchase of RAYOS/LODOTRA tablets from Jagotec for five years from the date of first launch of RAYOS/LODOTRA in a major country, as defined in the agreement, which was in April 2009. At December 31, 2013, the minimum remaining purchase commitment based on tablet pricing in effect under the agreement was $3,351. The agreement automatically renews on a yearly basis until either party provides two years advance written notice of termination. In April 2013, the agreement automatically renewed, and, therefore, the earliest the current agreement can expire according to this advance notice procedure is April 15, 2016.
	In May 2011, the Company entered into a manufacturing and supply agreement with sanofi-aventis U.S., and recently amended the agreement effective as of September 25, 2013. Pursuant to the agreement, as amended, sanofi-aventis U.S. is obligated to manufacture and supply DUEXIS to the Company in final, packaged form, and the Company is obligated to purchase DUEXIS exclusively from sanofi-aventis U.S. for the commercial requirements of DUEXIS in North America, South America and certain countries and territories in Europe, including the European Union member states and Scandinavia. At December 31, 2013, the Company had a binding purchase commitment to sanofi-aventis U.S. for DUEXIS of $10,286, of which $3,672 of such amount was delivered in the fourth quarter of 2013 and $6,614 is to be delivered in the first quarter of 2014.
	In November 2013, the Company and AstraZeneca entered in a supply agreement pursuant to which AstraZeneca agreed to supply VIMOVO to the Company for commercialization in the United States through December 31, 2014. As of December 5, 2013, the Company has been providing AstraZeneca with a forecast of its supply requirements, including any forecasts for its sublicensees. The first four months of each forecast is a binding purchase commitment and may not be changed without AstraZeneca’s written consent. As of December 31, 2013, the minimum binding purchase commitment to AstraZeneca was $4,402 and is to be delivered through the third quarter of 2014.
	Royalty Agreements
	In connection with the August 2004 development and license agreement with SkyePharma AG (“SkyePharma”) and Jagotec, a wholly-owned subsidiary of SkyePharma, regarding certain proprietary technology and know-how owned by SkyePharma, Jagotec is entitled to receive a single digit percentage royalty on net sales of RAYOS/LODOTRA and on any sub-licensing income, which includes any payments not calculated based on the net sales of RAYOS/LODOTRA, such as license fees, lump sum and milestone payments. Royalty expense recognized in cost of goods sold for the years ended December 31, 2013, 2012 and 2011 was $901, $539 and $455, respectively.
	Under the Pozen license agreement, the Company is required to pay Pozen a flat 10% royalty on net sales of VIMOVO and such other products sold by the Company, its affiliates or sublicensees during the royalty term, subject to minimum annual royalty obligations of $5.0 million in 2014 and $7.5 million each year thereafter, which minimum royalty obligations will continue for each year during which one of Pozen’s patents covers such products in the United States and there are no competing products in the United States. The royalty rate may be reduced to a mid-single digit royalty rate as a result of loss of market share to competing products. The Company’s obligation to pay royalties to Pozen will expire upon the later of (a) expiration of the last-to-expire of certain patents covering such products in the United States, and (b) ten years after the first commercial sale of such products in the United States.
	Contingencies
	The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.
	Indemnification
	In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.
	In accordance with its amended and restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. Additionally, the Company has entered, and intends to continue to enter, into separate indemnification agreements with its directors and executive officers. These agreements, among other things, require the Company to indemnify its directors and executive officers for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of the Company’s directors or executive officers, or any of the Company’s subsidiaries or any other company or enterprise to which the person provides services at the Company’s request. There have been no claims to date and the Company has a director and officer insurance policy that enables it to recover a portion of any amounts paid for future potential claims.

Legal_Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Legal Proceedings	'
	NOTE 13 – LEGAL PROCEEDINGS
	On February 15, 2012, the Company received a Paragraph IV Patent Certification from Par Pharmaceutical, Inc. advising that Par Pharmaceutical, Inc. had filed an Abbreviated New Drug Application (“ANDA”) with the FDA for a generic version of DUEXIS, containing 800 mg of ibuprofen and 26.6 mg of famotidine. In March 2012, the Company filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc.(collectively, “Par”) for filing an ANDA against DUEXIS and seeking an injunction to prevent the approval of Par’s ANDA and/or prevent Par from selling a generic version of DUEXIS. In January 2013, the Company filed a second suit against Par in the United States District Court for the District of Delaware claiming patent infringement of additional patents that have been issued for DUEXIS and seeking an injunction to prevent the approval of Par’s ANDA and/or prevent Par from selling a generic version of DUEXIS.
	On August 21, 2013, the Company entered into a settlement agreement (“Par settlement agreement”), and license agreement (“Par license agreement”) with Par relating to its patent infringement litigation. The Par settlement agreement provides for a full settlement and release by both the Company and Par of all claims that were or could have been asserted in the litigation and that arise out of the specific patent issues that were the subject of the litigation, including all resulting damages or other remedies.
	Under the Par license agreement, the Company granted Par a non-exclusive license (that is only royalty-bearing in some circumstances) to manufacture and commercialize Par’s generic version of DUEXIS in the United States after the generic entry date and to take steps necessary to develop inventory of, and obtain regulatory approval for, but not commercialize, Par’s generic version of DUEXIS prior to the generic entry date (collectively, the “License”). The License covers all patents owned or controlled by us during the term of the Par license agreement that would, absent the License, be infringed by the manufacture, use, sale, offer for sale, or importation of Par’s generic version of DUEXIS in the United States. Unless terminated sooner pursuant to the terms of the Par license agreement, the License will continue until the last to expire of the licensed patents and/or applicable periods of regulatory exclusivity.
	Under the Par license agreement, the generic entry date is January 1, 2023; however, Par may be able to enter the market earlier in certain circumstances. Such events relate to the resolution of potential future third party DUEXIS patent litigation, the entry of other third party generic versions of DUEXIS or certain specific changes in DUEXIS market conditions. Only in the event that Par enters the DUEXIS market due to the specified changes in DUEXIS market conditions will the License become royalty-bearing, with the royalty obligations ceasing upon the occurrence of one of the other events that would have allowed Par to enter the DUEXIS market.
	Under the Par license agreement, the Company also agreed not to sue or assert any claim against Par for infringement of any patent or patent application owned or controlled by the Company during the term of the Par license agreement based on the manufacture, use, sale, offer for sale, or importation of Par’s generic version of DUEXIS in the United States.
	The Par license agreement may be terminated by the Company or if Par commits a material breach of the agreement that is not cured or curable within 30 days after the Company provides notice of the breach. The Company may also terminate the Par license agreement immediately if Par or any of its affiliates initiate certain challenges to the validity or enforceability of any of the licensed patents or their foreign equivalents. In addition, the Par license agreement will terminate automatically upon termination of the Par settlement agreement.
	On March 13, 2013, the Company received purported Notice Letters that a Paragraph IV Patent Certification had been filed by Alvogen Pine Brook, Inc. (“Alvogen”) advising that Alvogen had filed an ANDA with the FDA for a generic version of RAYOS, containing up to 5 mg of prednisone. In the Notice Letters, Alvogen noted that as of March 13, 2013, the FDA had not accepted the ANDA for review. Alvogen has agreed that their Notice Letters do not constitute Notice as described in 21 U.S.C. 355(j)(2)(B).
	On July 15, 2013, the Company received a Paragraph IV Patent Certification from Watson Laboratories, Inc.—Florida (“Watson”) advising that Watson had filed an ANDA with the FDA for a generic version of RAYOS, containing up to 5 mg of prednisone. Watson has not advised the Company as to the timing or status of the FDA’s review of its filing. On August 26, 2013, the Company, together with Jagotec, filed suit in the United States District Court for the District of New Jersey against Watson, Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc., (collectively “WLF”) seeking an injunction to prevent the approval of the ANDA. The lawsuit alleges that WLF has infringed U.S. Patent Nos. 6,488,960, 6,677,326, 8,168,218, 8,309,124, and 8,394,407 by filing an ANDA seeking approval from the FDA to market generic versions of RAYOS containing 1 mg, 2 mg, and 5 mg of prednisone prior to the expiration of the patents. The subject patents are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The commencement of the patent infringement lawsuit stays, or bars, FDA approval of WLF’s ANDA for 30 months or until an earlier district court decision that the subject patents are not infringed or invalid.
	On or about August 12, 2013, the Company received a Notice of Opposition to a European patent covering LODOTRA, EP 2049123, filed by Laboratorios Liconsa, S.A. In the European Union, the grant of a patent may be opposed by one or more private parties.
	On September 12, 2013, the Company received a Paragraph IV Patent Certification from Par Pharmaceutical, Inc. advising that Par Pharmaceutical, Inc. had filed an ANDA with the FDA for a generic version of RAYOS, containing up to 5 mg of prednisone. On October 22, 2013, the Company, together with Jagotec, filed suit in the United States District Court for the District of New Jersey against Par seeking an injunction to prevent the approval of the ANDA. The lawsuit alleged that Par had infringed U.S. Patent Nos. 6,488,960, 6,677,326, 8,168,218, 8,309,124 and 8,394,407 by filing an ANDA seeking approval from the FDA to market generic versions of RAYOS prior to the expiration of the patents. The subject patents are listed in the FDA’s Orange Book. On November 20, 2013, the Company was notified by counsel for Par that Par Pharmaceutical, Inc. had elected to withdraw its ANDA with the FDA for a generic version of RAYOS containing 2 mg and 5 mg of prednisone. On December 5, 2013, the Company entered into a Stipulation of Dismissal with Par Pharmaceutical, Inc. whereby Par Pharmaceutical, Inc. agreed to withdraw its application to market a generic version of RAYOS.
	Currently, patent litigation is pending against five generic companies intending to market VIMOVO before the expiration of patents listed in the Orange Book. These cases are in the District of New Jersey and are grouped in three sets: (i) Dr. Reddy’s Laboratories, Inc. (“Dr. Reddy’s”); Lupin Pharmaceuticals Inc. (“Lupin”); Anchen Pharmaceuticals Inc. (“Anchen”) (collectively, the “DRL cases”); (ii) Mylan Laboratories Limited (collectively the “Mylan cases”); and (iii) Watson Pharma, Inc. (collectively, the “Watson cases”). The Company understands that Dr. Reddy’s has entered into a settlement with AstraZeneca with respect to patent rights directed to Nexium for the commercialization of VIMOVO, and that according to the settlement agreement, Dr. Reddy’s will not be able to commercialize VIMOVO under AstraZeneca’s Nexium patent rights until May 28, 2014. As part of the Company’s acquisition of the U.S. rights to VIMOVO, the Company has taken over and is responsible for the patent litigations that include the Pozen patents licensed to the Company under the Pozen license agreement.
	The DRL cases were filed on April 21, 2011, July 25, 2011, October 28, 2011, and October 23, 2013 and collectively include allegations of infringement of U.S. Patent Nos. 6,926,907 and 8,557,285. The Company understands the cases arise from Paragraph IV Notice Letters providing notice of the filing of an ANDA with the FDA seeking regulatory approval to market a generic version of VIMOVO before the expiration of the patents-in-suit. The Company understands the Dr. Reddy’s notice letters were dated March 11, 2011 and November 12, 2012; the Lupin notice letter was dated June 10, 2011; and the Anchen notice letter was dated September 16, 2011. The court has issued a claims construction order. The DRL cases do not have pretrial deadlines or a trial date set. The Company understands Anchen has recertified under Paragraph III and has filed a motion to dismiss on that basis.
	The Watson cases were filed on May 10, 2013 and October 23, 2013 and collectively include allegations of infringement of U.S. Patent Nos. 6,926,907 and 8,557,285. The Company understands the cases arise from a March 29, 2013 Paragraph IV Notice Letter providing notice of the filing of an ANDA with the FDA seeking regulatory approval to market a generic version of VIMOVO before the expiration of the patents-in-suit. The court has not yet set a trial date or schedule for the Watson cases.
	The Mylan cases were filed on June 28, 2013 and October 23, 2013 and collectively include allegations of infringement of U.S. Patent Nos. 6,926,907 and 8,557,285. The Company understands the cases arise from a May 16, 2013 Paragraph IV Notice Letter providing notice of the filing of an ANDA with the FDA seeking regulatory approval to market a generic version of VIMOVO before the expiration of the patents-in-suit. The court has not yet set a trial date or schedule for the Mylan cases.

Debt_Agreements

Debt Agreements	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Agreements	'
	NOTE 14 – DEBT AGREEMENTS
	The Company’s outstanding debt balances as of December 31, 2013 and 2012, consisted of the following:
			As of December 31,
			2013			2012
	Convertible Senior Notes		$	150,000		$	—
	Senior Secured Loan			—			61,843
	Current debt maturities			—			(11,935	)
	Debt discount			(39,238	)		(13,042	)
	Long-term debt, net of current maturities		$	110,762		$	36,866
	Senior Secured Loan
	In February 2012, the Company entered into a $60,000 senior secured loan facility with a group of institutional lenders (the “Senior Secured Loan”). Under the terms of the Senior Secured Loan, the outstanding principal was to accrue interest until maturity in January 2017 at a rate of 17% per annum, payable quarterly unless repaid earlier. The Senior Secured Loan allowed the Company to pay the full 17% interest when due or pay 12% interest in cash and the remaining 5% interest in the form of incremental debt (i.e., payment in kind borrowings). During 2012, the Company elected to pay the 12% interest in cash, and the remaining 5% interest due of $1,842 was added to the principal loan balance as a payment in kind borrowing. During 2013, the Company again elected to pay the 12% interest in cash, and the remaining 5% interest due of $3,001 was added to the principal loan balance as a payment in kind borrowing.
	On September 7, 2012, the Company and the lenders entered into an amendment to the Senior Secured Loan (the “Senior Secured Loan Amendment”), whereby certain affirmative covenants under the Senior Secured Loan relating to minimum levels of liquidity and net revenue were modified.
	In lieu of paying a cash fee in consideration for entering into the Senior Secured Loan Amendment, the Company agreed to issue an aggregate of 1,250,000 shares of the Company’s common stock to the lenders. The fair value of the common stock issued in connection with the Senior Secured Loan Amendment was $5,075 and was classified as debt discount in the Company’s consolidated balance sheet.
	Beginning in April 2013, and each quarter thereafter, the lenders had the option to require the Company to repay $3,978 of the loan principal. The Company could also prepay the loan at any time, subject to certain prepayment premiums. In March 2013, one of the lenders notified the Company of its election to request a partial repayment of the loan principal, effective on the April 1, 2013 interest payment date and each quarter thereafter. In March 2013 and June 2013, a second lender notified the Company of its election to request a partial repayment of the loan principal, effective on the April 1, 2013 and July 1, 2013 interest payment dates, respectively. Accordingly, on April 1, 2013, the Company made a payment of $5,836, which consisted of $3,978 in principal and $1,858 in interest. Additionally, on July 1, 2013, the Company made a payment of $5,761, which consisted of $3,978 in principal and $1,783 in interest. In September 2013, the Company was notified by the first lender mentioned above of its election to rescind its on-going request of a partial repayment of the loan principal, effective starting with the fourth quarter of 2013.
	In connection with the Senior Secured Loan, the Company also issued warrants to the lenders to purchase up to an aggregate of 3,277,191 shares of common stock at an exercise price of $0.01 per share, all of which have been exercised. The Senior Secured Loan was secured by a lien on substantially all of the Company’s assets including intellectual property, and the Company pledged all of its equity interests in Horizon Pharma USA, Inc. and 65% of its equity interests in Horizon Pharma AG.
	On November 22, 2013, the Company used $70,409 of the proceeds from the Convertible Senior Notes to repay the Senior Secured Loan. As a result of the extinguishment of the Senior Secured Loan, the Company incurred a $26,404 loss on debt extinguishment from the write-off of the remaining debt discount and deferred financing costs, pre-payment penalty, interest and end of loan fees. The loss on the extinguishment of debt is included in interest expense in the consolidated statement of comprehensive loss for the year ended December 31, 2013.
	Convertible Senior Notes
	On November 18, 2013, the Company entered into note purchase agreements with investors to issue $150,000 aggregate principal amount of Convertible Senior Notes. The note purchase agreements contain customary representations, warranties, covenants and closing conditions. The Convertible Senior Notes were issued on November 22, 2013. The Company received net proceeds of $143,598 from the sale of the Convertible Senior Notes, after deducting fees and expenses of $6,402. The Convertible Senior Notes are governed by an Indenture, dated as of November 22, 2013, between the Company and U.S. Bank National Association, as trustee. The Convertible Senior Notes bear interest at a rate of 5.00% per year, payable in arrears on May 15 and November 15 of each year, beginning on May 15, 2014. The Convertible Senior Notes will mature on November 15, 2018, unless earlier repurchased or converted.
	The Company used a portion of the proceeds from the Convertible Senior Notes to purchase $18,675 related to a capped call transaction. The capped call transaction is comprised of a net settled purchased call option and a net settled written call option. The Company purchased the call option with an initial strike price of $5.364, which was equal to the initial conversion price, and sold a call option with a strike price of $6.705, which is equal to the cap price. The number of options underlying the capped call is 150,000 or the equivalent to the number of $1,000 Convertible Senior Notes initially issued by the Company.
	The Convertible Senior Notes were sold at a price equal to 100% of the principal amount thereof and are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding August 15, 2018 only under certain conditions. Prior to August 15, 2018, the Convertible Senior Notes will be convertible, at the option of the holders thereof, only under the following circumstances:
		1	Conversion upon Satisfaction of Sale Price Condition: During any fiscal quarter beginning after June 30, 2014, if the closing price of the Company’s common stock for at least 20 trading days during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day.
		2	Conversion upon Satisfaction of Trading Price Condition: The Convertible Senior Notes can be surrendered for conversion during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of Convertible Senior Notes was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate on such date.
		3	Conversion upon Specified Distributions: If the Company elects to:
		i.	issue to all or substantially all holders of the Company’s common stock any rights, options or warrants (other than in connection with a stockholder rights plan) entitling them, for a period of not more than 45 calendar days after the declaration date for such issuance, to subscribe for or purchase shares of the Company’s common stock at a price per share that is less than the average of the last reported sale prices of the Company’s common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such issuance; or
		ii.	distribute to all or substantially all holders of the Company’s common stock our assets, securities or rights to purchase our securities, which distribution has a per share value, as reasonably determined by the Company’s board of directors or a committee thereof, exceeding 10% of the last reported sale price of the Company’s common stock on the trading day preceding the date of announcement for such distribution.
		4	Conversion upon Specified Corporate Events: If (i) a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs or (ii) the Company is party to a consolidation, merger, binding share exchange, or transfer or lease of all or substantially all of its consolidated assets pursuant to which the Company’s common stock would be converted into cash, securities or other assets.
	On or after August 15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date for the Convertible Senior Notes, holders will be able to convert their Convertible Senior Notes at their option at the conversion rate then in effect at any time, regardless of these conditions.
	Subject to certain limitations, the Company may settle conversions of the Convertible Senior Notes by paying or delivering, as the case may be, cash, shares of common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election. If the Company undergoes a fundamental change prior to the maturity date of the Convertible Senior Notes, the holders may require the Company to repurchase for cash all or any portion of their Convertible Senior Notes at a price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus accrued and unpaid interest.
	The conversion rate for the Convertible Senior Notes will initially be 186.4280 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an initial conversion price of approximately $5.36 per share of common stock); provided that unless and until the Company obtains stockholder approval to issue more than 13,164,951 shares of its common stock, which is 19.99% of the Company’s common stock outstanding on November 18, 2013, upon conversion of the Convertible Senior Notes in accordance with the listing standards of The NASDAQ Global Market, the number of shares of common stock deliverable upon conversion will be subject to a “conversion share cap.” Unless and until such stockholder approval is obtained, the Company is required to settle conversions of the Convertible Senior Notes in cash up to their principal amount, shares for any conversion spread, and, if the number of shares deliverable for the conversion spread exceeds the conversion share cap, cash in lieu of shares that would otherwise be deliverable. The conversion rate of the Convertible Senior Notes, and the corresponding conversion price, is subject to adjustment for certain events, but will not be adjusted for accrued and unpaid interest.
	As of December 31, 2013, the carrying value of the Convertible Senior Notes approximated their fair value due to the recent issuance of such Convertible Senior Notes. Additionally, pursuant to a number of factors outlined in ASC Topic 815, Derivative and Hedging, the conversion option in the Convertible Senior Notes were deemed an embedded derivative that required bifurcation and separate accounting, As such, the Company ascertained the value of the conversion option as if separate from the convertible issuance and appropriately recorded that value as a derivative liability. Accordingly, a derivative liability and a corresponding debt discount in the amount of $40,110 were recorded at November 22, 2013. The debt discount will be charged to interest expense ratably over the life of the convertible debt. The effective interest rate computed on the Convertible Senior Notes was 11.22%.
	The derivative liability will be subject to revaluation on a quarterly basis to reflect the market value change of the embedded conversion option. At December 31, 2013, the Company conducted a fair value assessment to ascertain the market value of the embedded derivative. Due primarily to changes in the Company’s common stock value, the Company recorded a $69,300 expense in its results of operations for the three and twelve months ended December 31, 2013 to properly reflect the fair value of the embedded derivative at $109,410 as of December 31, 2013. Upon receiving shareholder approval, the derivative liability will be re-measured on such date of approval to determine the fair value. Any gains or losses as a result of the re-measurement of the derivate liability will be recorded in the Company’s results of operations during that period and the entire fair value of the derivative liability will be recorded to the Company’s additional paid-in capital upon conversion.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	NOTE 15 – STOCKHOLDERS’ EQUITY
	In August 2012, the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”) pursuant to which the Company may sell its common stock through Cowen in at-the-market (“ATM”) offerings. Subject to the terms and conditions of the sales agreement, Cowen may sell the shares by methods deemed to be an ATM offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, including sales made through The NASDAQ Global Market, on any other existing trading market for the Company’s common stock or to or through a market maker. On March 25, 2013, the Company requested Cowen to begin making sales under the sales agreement and provided Cowen both daily volume and minimum price restrictions under which Cowen could sell the Company’s common stock. Cowen has not sold shares under the ATM since July 2013. As of December 31, 2013, Cowen had sold a cumulative total of 2,448,575 shares of the Company’s common stock with gross proceeds to the Company of $6,238.
	In September 2013, warrants to purchase an aggregate of 1,365,497 shares of the Company’s common stock were exercised in cashless exercises, resulting in the issuance of 1,360,746 shares of common stock.

CoPromotion_Agreement

Co-Promotion Agreement	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Co-Promotion Agreement	'
	NOTE 16 – CO-PROMOTION AGREEMENT
	In June 2012, the Company entered into a co-promotion agreement with Mallinckrodt (the “Mallinckrodt Agreement”), pursuant to which the Company engaged Mallinckrodt on a non-exclusive basis to promote DUEXIS in the United States, excluding Puerto Rico and any other territories or possessions. Under the terms of the Mallinckrodt Agreement, Mallinckrodt agreed to use commercially reasonable efforts to promote DUEXIS to an agreed list of physician promotion targets. Mallinckrodt was required to achieve minimum levels of prescriptions from targeted physicians on a quarterly basis during the term of the agreement, and the Company agreed not to grant to any third party the right to co-promote DUEXIS to those targeted physicians in the agreed upon territory during the term, other than an existing third party agreement that has since been terminated. Under the terms of the Mallinckrodt Agreement, the Company was responsible for the manufacture, supply and distribution of DUEXIS.
	Each party could terminate the agreement early upon certain failures to achieve minimum levels of prescriptions for a specified period of time. On June 1, 2013, the Company provided written notice to Mallinckrodt of termination of the Mallinckrodt Agreement, effective 30 days after the date of such notice. The Mallinckrodt Agreement was terminated as a result of Mallinckrodt not achieving minimum levels of prescriptions from targeted physicians for two consecutive quarters during the period prior to September 30, 2013.

Equity_Incentive_Plans

Equity Incentive Plans	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Equity Incentive Plans	'
	NOTE 17 – EQUITY INCENTIVE PLANS
	Employee Stock Purchase Plan
	In July 2010, the Company’s board of directors adopted the 2011 Employee Stock Purchase Plan (the “2011 ESPP”). In June 2011, the Company’s stockholders approved the 2011 ESPP, and it became effective upon the signing of the underwriting agreement related to the Company’s initial public offering in July 2011. The Company reserved a total of 463,352 shares of common stock for issuance under the 2011 ESPP. The 2011 ESPP provides that an additional number of shares will automatically be added to the shares authorized for issuance under the 2011 ESPP each year on January 1, until 2021. The number of shares added each year will be equal to the least of: (a) 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; (b) 1,053,074 shares of common stock; or (c) a number of shares of common stock that may be determined each year by the Company’s board of directors that is less than (a) and (b). Subject to certain limitations, the Company’s employees may elect to have 1% to 15% of their compensation withheld through payroll deductions to purchase shares of common stock under the 2011 ESPP. Employees purchase shares of common stock at a price per share equal to 85% of the lower of the fair market value at the start or end of the six-month offering period.
	On December 5, 2013, pursuant to the terms of the 2011 ESPP, the Company’s board of directors approved an increase in the number of shares available for issuance under the 2011 ESPP of 1,053,074 shares, effective January 1, 2014. As of December 31, 2013, 350,547 shares have been issued and an aggregate of 412,805 shares of common stock were authorized and available for future grants under the 2011 ESPP.
	Stock-Based Compensation Plans
	In October 2005, the Company adopted the 2005 Stock Plan (the “2005 Plan”). The 2005 Plan provides for the granting of stock options to employees and consultants of the Company. Options granted under the 2005 Plan may be either incentive stock options or nonqualified stock options. Upon the signing of the underwriting agreement related to the Company’s initial public offering, on July 28, 2011, no further option grants were made under the 2005 Plan. As of July 28, 2011, the 460,842 shares of common stock reserved for future issuance and the 1,304,713 shares of common stock reserved for future issuance upon the exercise of options outstanding under the 2005 Plan were transferred to the 2011 Equity Incentive Plan (the “2011 EIP”), as described below. All stock options granted under the 2005 Plan prior to the offering continue to be governed by the terms of the 2005 Plan.
	In July 2010, the Company’s board of directors adopted the 2011 EIP. In June 2011, the Company’s stockholders approved the 2011 EIP, and it became effective upon the signing of the underwriting agreement related to the Company’s initial public offering on July 28, 2011. The 2011 EIP had an initial reserve of 3,366,228 shares of common stock, including 460,842 shares of common stock previously reserved for future issuance under the 2005 Plan, 1,304,713 shares of common stock reserved for future issuance upon the exercise of options outstanding under the 2005 Plan as of the 2011 EIP’s effective date and 1,600,673 new shares of common stock reserved. The 2011 EIP provides that an additional number of shares will automatically be added to the shares authorized for issuance each year on January 1, until 2021. The number of shares added each year will be equal to the least of: (a) 5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; (b) 1,474,304 shares of common stock; or (c) a number of shares of common stock that may be determined each year by the Company’s board of directors that is less than (a) and (b). As of December 31, 2013, there were 78,795 shares available for future grants under the 2011 EIP. On December 5, 2013, pursuant to the terms of the Company’s 2011 EIP, the Company’s board of directors approved an increase in the number of shares available for issuance under the 2011 EIP of 1,474,304 shares, effective January 1, 2014.
	On November 7, 2013, November 16, 2013 and March 3, 2014, the Company’s board of directors approved amendments to the Company’s 2011 EIP to reserve an additional 200,000 shares, 800,000 shares and 730,000 shares of the Company’s common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company (or following a bona fide period of non-employment with the Company), as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules (“Rule 5635(c)(4)”). On January 10, 2014, the Company’s board of directors approved an amendment to the 2011 EIP to increase the number of shares available for issuance under the 2011 EIP by 703,400 shares (the “January 2014 amendment”), with such increase to the number of shares available for issuance under the 2011 EIP subject to stockholder approval of the January 2014 amendment. As of December 31, 2013, there were 674,400 shares available for future grants under the 2011 EIP pursuant to Rule 5635(c)(4).
	Under the 2011 EIP, the board of directors, or a committee of the board of directors, may grant incentive and nonqualified stock options, stock appreciation rights, restricted stock units, or restricted stock awards to employees, directors and consultants to the Company or any subsidiary of the Company. Under the terms of the 2011 EIP, the exercise price of stock options may not be less than 100% of the fair market value on the date of grant and their term may not exceed ten years.
	The following table summarizes stock options activity under the 2011 EIP for the year ended December 31, 2013 as follows:
		Options			Weighted		Weighted Average		Aggregate
					Average		Remaining		Intrinsic Value
					Exercise  Price		Contractual Term		(in thousands)
	Outstanding as of December 31, 2012		2,746,918		$	8.85
	Granted		2,158,950		$	2.84
	Exercised		(41,820	)	$	3.88
	Forfeited		(452,968	)	$	3.88
	Outstanding as of December 31, 2013		4,411,080		$	6.47		7.9 years	$	13,283
	Exercisable as of December 31, 2013		2,079,728		$	9.57		6.8 years	$	3,860
	The following table summarizes the Company’s outstanding stock options at December 31, 2013:
		Options Outstanding							Options Exercisable
	Exercise Price Ranges	Number of options			Weighted		Weighted		Number		Weighted
		outstanding			Average		Average		Exercisable		Average
					Exercise Price		Remaining				Exercise
							Contractual				Price
							Term
	$1.36 - $3.97		2,079,203		$	2.63		9.1 years		432,699	$	2.65
	$4.10 - $5.20		1,039,318			4.98		7.5 years		651,196		5.02
	$7.48 - $12.94		935,627			10.04		7.0 years		645,136		11.01
	$13.47 - $17.22		106,568			13.91		5.6 years		104,547		13.85
	$20.78 - $28.83		250,364			28.05		651 years		246,150		28.18
			4,411,080		$	6.47		7.9 years		2,079,728	$	9.57
	During the years ended December 31, 2013, 2012 and 2011, the Company granted stock options to purchase an aggregate of 2,158,950, 516,325 and 1,256,339 shares of common stock, respectively, with a weighted average grant date fair value of $2.23, $3.44 and $5.77, respectively.
	The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The determination of the fair value of each stock option is affected by the Company’s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company’s expected stock price volatility over the expected life of the awards and actual and projected stock option exercise behavior. The weighted average fair value per share of stock option awards granted during the years ended December 31, 2013, 2012 and 2011, and assumptions used to value stock options, are as follows:
		For the Years Ended Deceber 31,
		2013			2012		2011
	Dividend yield		—			—		—
	Risk-free interest rate		1.20%			1.00%		1.20%
	Weighted average volatility		86.70%			89.00%		89.30%
	Expected life (in years)		5.98			5.96		6
	Weighted average grant date fair value per share of options granted	$	2.8		$	2.5	$	4.2
	Dividend yields
	The Company has never paid dividends and does not anticipate paying any dividends in the near future. The loan agreements governing the Senior Secured Loan contain covenants that include, among other things, restrictions on paying dividends, subject to customary exceptions.
	Risk-Free Interest Rate
	The Company determined the risk-free interest rate by using a weighted average assumption equivalent to the expected term based on the U.S. Treasury constant maturity rate as of the date of grant.
	Volatility
	The Company used an average historical stock price volatility of comparable companies to be representative of future stock price volatility, as the Company did not have sufficient trading history for its common stock.
	Expected Term
	Given the Company’s limited historical exercise behavior, the expected term of options granted was determined using the “simplified” method since the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. Under this approach, the expected term is presumed to be the average of the vesting term and the contractual life of the option.
	Forfeitures
	As stock-based compensation expense recognized in the consolidated statements of operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures based on actual forfeiture experience, analysis of employee turnover and other factors. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	Restricted Stock Units
	The following table summarizes restricted stock unit activity for the year ended December 31, 2013 as follows:
		Number			Weighted Average
		of Units			Grant-Date Fair
					Value Per Units
	Outstanding as of December 31, 2012		232,158		$	4.92
	Granted		831,004		$	2.95
	Vested		(174,213	)	$	6.05
	Forfeited		(55,948	)	$	2.86
	Outstanding as of December 31, 2013		833,001		$	2.86
	During the years ended December 31, 2013, 2012 and 2011, the Company granted 730,000, 520,000 and 304,890, respectively, restricted stock units to acquire shares of the Company’s common stock to its employees. The restricted stock units vest over a four-year period on each anniversary of the vesting commencement date. In addition, in December 2013, the Company granted 101,004 fully vested deferred issuance restricted stock units to the Company’s named executive officers in connection with a one-time bonus payment associated with the completion of the Company’s acquisition of the U.S. rights to VIMOVO.
	The following table summarizes share-based compensation expense included in the Company’s consolidated statements of operations for the years ended December 31, 2013, 2012 and 2011:
	For the Years Ended December 31,
	2013			2012		2011
Share-based compensation expense:
Research and development	$	1,054		$	1,186	$	760
Sales and marketing		1,465			1,090		451
General and administrative		2,495			2,385		1,319
Net effect of share-based compensation expense on net loss	$	5,014		$	4,661	$	2,530
No income tax benefit has been recognized relating to stock-based compensation expense and no tax benefits have been realized from exercised stock options, due to the Company’s net loss position. As of December 31, 2013, the Company estimates that pre-tax unrecognized compensation expense of $7,459 for all unvested share-based awards, including both stock options and restricted stock units, will be recognized through the fourth quarter of 2016, with $5,792 in pre-tax compensation expense estimated to be recognized during the year ended December 31, 2014. The Company expects to satisfy the exercise of stock options and future distribution of shares of restricted stock by issuing new shares of its common stock which have been reserved under the 2011 EIP.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	NOTE 18 – RELATED PARTY TRANSACTIONS
	The Company has entered into consulting agreements with three stockholders, two of whom previously served as directors of Horizon Pharma USA. Two of the consulting agreements terminated as of December 31, 2011, while one remains in effect. In addition, the Company’s wholly-owned subsidiary, Horizon Pharma AG, has entered into a consulting agreement with a former owner and majority shareholder of Nitec. For the years ended December 31, 2013, 2012 and 2011, the Company paid $691, $716 and $678, respectively, in consulting fees to the related parties.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	NOTE 19 – INCOME TAXES
	The Company accounts for income taxes based upon an asset and liability approach. Deferred tax assets and liabilities represent the future tax consequences of the differences between the financial statement carrying amounts of assets and liabilities versus the tax basis of assets and liabilities. Under this method, deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards. Deferred tax liabilities are recognized for taxable temporary differences. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The impact of tax rate changes on deferred tax assets and liabilities is recognized in the year that the change is enacted.
	The components of the benefit for income taxes were as follows for the years ended December 31, 2013, 2012 and 2011:
			For the Years Ended December 31,
			2013			2012			2011
	Current provision
	Federal		$	—		$	—		$	—
	State			4			4			3
	Foreign			43			35			28
	Total current provision			47			39			31
	Deferred benefit
	Federal			—			—			—
	State			—			—			—
	Foreign			(1,168	)		(5,210	)		(14,714	)
	Total deferred benefit			(1,168	)		(5,210	)		(14,714	)
	Total benefit for income taxes		$	(1,121	)	$	(5,171	)	$	(14,683	)
	Total benefit for income taxes was $1,121, $5,171 and $14,683 for the years ended December 31, 2013, 2012 and 2011, respectively. The $4,050 decrease in the income tax benefit during the year ended December 31, 2013 was primarily attributable to the absence of one-time tax benefits in 2013 that were recorded during 2012. On July 26, 2012, the FDA approved RAYOS, which resulted in the reclassification of $35,456, from an indefinite-lived intangible asset to a finite-lived intangible asset. The reclassification required the Company to amortize this asset over the estimated useful life of the asset, which resulted in a corresponding reduction to the Company’s net deferred tax liabilities and the recognition of a one-time net income tax benefit of $4,258 that was recorded as an additional income tax benefit during the third quarter of 2012.
	During the year ended December 31, 2011, total benefit for income taxes was $14,683. The increase in income tax benefit during this period compared to the year ended December 31, 2010 was associated with a reduction in the Company’s deferred income tax liabilities and a corresponding income tax benefit recorded as a result of intangible asset impairment charge. During the fourth quarter of 2011, the Company performed its annual impairment test related to its indefinite-lived intangible asset and determined that the carrying value of its indefinite-lived in process research and development (“IPR&D”) asset was greater than the fair value of this asset. Accordingly, the Company recorded an intangible asset impairment charge of $69,621 associated with the Company’s IPR&D asset during 2011, which reduced the Company’s deferred income tax liability and increased the income tax benefit for the period.
	The Company’s loss before benefit for income taxes by jurisdiction for the years ended December 31, 2013, 2012 and 2011 is as follows:
			For the Years Ended December 31,
			2013			2012			2011
	United States		$	(139,347	)	$	56,038		$	(43,148	)
	International			(10,779	)		(149,003	)		(84,800	)
	Loss before benefit for income taxes		$	(150,126	)	$	(92,965	)	$	(127,948	)
	A reconciliation between the statutory federal income tax and the Company’s effective tax is as follows:
			For the Years Ended December 31,
			2013			2012			2011
	U.S. federal income taxes at statutory tax rate		$	(52,543	)	$	(32,538	)	$	(44,781	)
	Stock based compensation			1,107			1,063			658
	Foreign tax rate differential			2,019			4,376			14,994
	Deferred taxes not benefited			23,921			21,715			14,499
	Derivative liability			24,255			—			—
	Research and development credit			120			(5	)		(79	)
	Other			—			218			26
	Effective income taxes		$	(1,121	)	$	(5,171	)	$	(14,683	)
	The tax effects of the temporary differences and net operating losses that give rise to significant portions of deferred tax assets and liabilities are as follows:
			As of December 31,
			2013			2012			2011
	Deferred tax assets:
	Net operating loss carryforwards		$	121,001		$	97,724		$	68,689
	Derivative liability			14,799			—			—
	Accruals and reserves			7,073			5,144			1,906
	Original issuance discount related to capped call			6,740			—			—
	Contingent royalties			3,122			—			—
	Research and development credits			2,571			2,445			2,447
	Foreign intangible assets			63			76			90
	Total deferred tax assets			155,369			105,389			73,132
	Valuation allowance			(128,422	)		(95,970	)		(68,194	)
	Deferred tax assets, net of valuation allowance			26,947			9,419			4,938
	Deferred tax liabilities:
	Debt discount		$	14,477		$	—		$	—
	In-process research and development			—			—			7,354
	Developed technology			13,009			13,827			7,145
	Intangible assets			2,823			—			—
	Total deferred tax liabilities			30,309			13,827			14,499
	Net deferred income tax liability		$	3,362		$	4,408		$	9,561
	The increase in the deferred tax valuation allowance was $32,452, $27,776 and $14,213 for the years ended December 31, 2013, 2012 and 2011, respectively. The increase in the deferred tax valuation allowance in 2013 was primarily the result of higher federal and state net operating losses, which were fully reserved for due to the uncertainty surrounding the realization of these assets. A reconciliation of the beginning and ending amounts of the valuation allowance for the years ended December 31, 2013, 2012 and 2011 were as follows:
	Valuation allowance at December 31, 2010		$	(53,981	)
	Increase for current year activity			(14,213	)
	Valuation allowance at December 31, 2011		$	(68,194	)
	Increase for current year activity			(32,034	)
	Release in valuation allowance (1)			4,258
	Valuation allowance at December 31, 2012		$	(95,970	)
Increase for current year activity			(32,452	)
Valuation allowance at December 31, 2013		$	(128,422	)
-1	In connection with the FDA approval of RAYOS on July 26, 2012, the Company reclassified its indefinite-lived IPR&D intangible asset to a finite-lived developed technology intangible asset and began amortizing the asset to cost of goods during the third quarter of 2012. The reclassification to developed technology required the Company to reassess its deferred tax positions, which indicated that it was more likely than not that a greater portion of the Company’s deferred tax assets would be realized as a result of the reclassification of its intangible asset from indefinite-lived to finite-lived. As a result of this assessment, the Company reduced its deferred tax asset valuation allowances, which resulted in a corresponding reduction to the Company’s net deferred tax liabilities and the recognition of a one-time net income tax benefit of $4,258 that was recorded as an additional benefit for income taxes during the third quarter of 2012.
As of December 31, 2013, the Company had net operating loss carryforwards of approximately $275,430, $123,257 and $91,804 available to reduce future taxable income, if any, for federal, state, and foreign income tax purposes, respectively. Net operating loss carryforwards for state and federal income tax purposes will begin to expire in 2015 and 2025, respectively. Utilization of the net operating loss carryforwards may be subject to annual limitations as prescribed by federal and state statutory provisions. The annual limitation may result in the expiration of net operating loss carryforwards prior to its utilization. The Company’s net operating loss of $995, when realized, will be recorded through stockholders’ equity.
As of December 31, 2013, the Company had research and development credit carryforwards for federal and state income tax purposes of approximately $2,745 and $394, respectively, available to reduce future taxable income. The federal research and development credits will expire beginning in 2026 if not utilized while the state research and development credits have an unlimited carryforward period.
The Company has provided a full valuation allowance for its deferred tax assets at December 31, 2013 due to the uncertainty surrounding the future realization of these assets. During the year ended December 31, 2013, $6,740 of the valuation allowance related to the deferred tax asset, which was created as a result of the original debt discount associated with the capped call transaction, was recorded to stockholders’ equity. As this deferred tax asset which was recorded through stockholders’ equity is removed, the related valuation allowance will also be removed through stockholders’ equity.
In September 2012, the sale of the Company’s common stock and warrants to purchase shares of the Company’s common stock in a public equity offering triggered an “ownership change” as prescribed by Section 382 of the Internal Revenue Code of 1986, as amended, which generally imposes an annual limitation on the amount of net operating loss carryforwards and associated built-in losses that may be used to offset taxable income when a corporation has undergone certain changes in stock ownership. The Company estimates that these annual limits will be a cumulative carryforward of $49,893 in 2014, and at a minimum, $22,001 for each of 2015 and 2016 assuming only the carryforward limitation. The net operating loss carryforward limitation is cumulative such that any use of the carryforwards below the limitation in one year will result in a corresponding increase in the limitation for the subsequent tax year.
The Company accounts for the uncertainty in income taxes by utilizing a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or are expected to be taken on an income tax return. The changes in the Company’s uncertain income tax positions for the years ended December 31, 2013, 2012 and 2011 consisted of the following:
		For the Years Ended December 31,
		2013			2012			2011
Beginning balance		$	442		$	442		$	424
Tax positions related to current year:
Additions			51			2			34
Reductions			—			—			—
			51			2			34
Tax positions related to prior years:
Additions			—			—			—
Reductions			(2	)		(2	)		(16	)
Settlements			—			—			—
Lapses in statutes of limitations			—			—			—
Additions from current year acquisitions			—			—			—
			(2	)		(2	)		(16	)
Ending balance		$	491		$	442		$	442
The Company has assessed that its liability for unrecognized income tax benefits will not significantly change within the next twelve months. If these unrecognized tax benefits are recognized, the impact on the Company’s effective tax rate would be immaterial. Additionally, there was no interest or penalties accrued at December 31, 2013 and 2012, respectively, due to the Company’s net operating loss position.
The Company files income tax returns in the U.S. federal and in various state and foreign jurisdictions. At December 31, 2013, all open tax years in the federal and some state jurisdictions date back to 2005 due to the taxing authorities’ ability to adjust operating loss carryforwards. No changes in settled tax years have occurred through December 31, 2013 and the Company does not anticipate there will be a material change in the total amount of unrecognized tax benefits within the next 12 months.

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
Employee Benefit Plans	'
	NOTE 20 – EMPLOYEE BENEFIT PLANS
	The Company sponsors a defined contribution 401(k) retirement savings plan covering all of its U.S. employees, whereby an eligible employee may elect to contribute a portion of his or her salary on a pre-tax basis, subject to applicable federal limitations. Under the terms of the plan, the Company is not required to make any discretionary matching of employee contributions. For the years ended December 31, 2013, 2012 and 2011, the Company did not record any expense under the plan.
	The Company’s wholly-owned subsidiary, Horizon Pharma AG, sponsors a defined benefit savings plan covering all of its employees in Switzerland and a defined contribution plan for its employees in Germany. For the years ended December 31, 2013, 2012 and 2011, the Company recognized expenses of $52, $52 and $55, respectively, under these plans.

Selected_Quarterly_Financial_I

Selected Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Selected Quarterly Financial Information (Unaudited)	'
	NOTE 21 – SELECTED QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
	The following table provides a summary of selected financial results of operations by quarter for the years ended December 31, 2013 and 2012 as follows:
	2013		First			Second			Third			Fourth
	Net sales (1)		$	8,693		$	11,131		$	24,112		$	30,080
	Gross profit			4,924			8,737			20,905			24,825
	Loss from operations			(18,544	)		(15,804	)		(2,744	)		(5,762	)
	Net loss			(22,171	)		(18,441	)		(5,492	)		(102,901	)
	Net loss per common share-basic and diluted		$	(0.36	)	$	(0.29	)	$	(0.08	)	$	(1.56	)
	2012		First			Second			Third			Fourth
	Net sales (1)		$	2,485		$	3,681		$	6,319		$	6,359
	Gross profit			456			986			2,711			2,816
	Loss from operations			(19,788	)		(18,345	)		(18,714	)		(22,026	)
	Net loss			(23,726	)		(22,782	)		(16,953	)		(24,333	)
	Net loss per common share-basic and diluted		$	(0.98	)	$	(0.68	)	$	(0.47	)	$	(0.40	)
	-1	The net sales amounts listed above for the First, Second and Third quarters of 2013 have been revised from $9,171, $12,254 and $26,218, respectively, and the net sales amounts listed above for the First, Second, Third and Fourth quarters of 2012 have been revised from $2,523, $3,842, $6,520 and $6,747, respectively, reflecting the reclassification of wholesaler service fees from cost of goods sold to sales discounts and allowances. See Note 1 “The Company” in the notes to the Company’s consolidated financial statements included in this Annual Report on Form 10-K.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“GAAP”) and in accordance with the instructions for Form 10-K and Article 3 of Regulation S-X. The consolidated financial statements include the accounts of the Company and its wholly-owned consolidated subsidiaries.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the Company’s accounts and those of its wholly-owned subsidiaries: Horizon Pharma USA, Inc. in Deerfield, IL, Horizon Pharma AG in Reinach, Switzerland and Horizon Pharma GmbH in Mannheim, Germany. All intercompany accounts and transactions have been eliminated.
Segment Information	'
	Segment Information
	The Company operates as one segment. Management uses one measure of profitability and does not segment its business for internal reporting.
Use of Estimates	'
	Use of Estimates
	The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Foreign Currency Translation and Transactions	'
	Foreign Currency Translation and Transactions
	The reporting currency of the Company and its subsidiaries is the U.S. dollar.
	The U.S. dollar is the functional currency for the Company’s U.S. based businesses and the Euro is the functional currency for its subsidiaries in Switzerland and Germany. Foreign currency-denominated assets and liabilities of these subsidiaries are translated into U.S. dollars based on exchange rates prevailing at the end of the period, revenues and expenses are translated at average exchange rates prevailing during the corresponding period, and stockholders’ equity (deficit) accounts are translated at historical exchange rates as of the date of any equity transaction. The effects of foreign exchange gains and losses arising from the translation of assets and liabilities of those entities where the functional currency is not the U.S. dollar are included as a component of accumulated other comprehensive income (loss).
	Gains and losses resulting from foreign currency translations are reflected within the Company’s results of operations. During the years ended December 31, 2013 and 2012, the Company recorded gains from foreign currency translations of $1,206 and $489, respectively, compared to a loss from foreign currency translations during the year ended December 31, 2011 of $1,023. The Company does not currently utilize and has not in the past utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure.
Revenue Recognition	'
	Revenue Recognition
	Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured. Some of the Company’s agreements contain multiple elements and in accordance with these agreements, the Company may be eligible for upfront license fees, marketing or commercial milestones and payment for product deliveries.
	Revenue from upfront license fees
	The Company recognizes revenues from the receipt of non-refundable, upfront license fees. In situations where the licensee is able to obtain stand-alone value from the license and no further performance obligations exist on the Company’s part, revenues are recognized on the earlier of when payments are received or collection is reasonably assured. Where continuing involvement by the Company is required in the form of technology transfer, product manufacturing or technical support, revenues are deferred and recognized over the term of the agreement.
	Revenue from milestone receipts
	Milestone payments are recognized as revenue based on achievement of the associated milestones, as defined in the relevant agreements. Revenue from a milestone achievement is recognized when earned, as evidenced by acknowledgment from the Company’s partner, provided that (1) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, (2) the milestone represents the culmination of an earnings process and (3) the milestone payment is non-refundable. If all of these criteria are not met, revenue from the milestone achievement is recognized over the remaining minimum period of the Company’s performance obligations under the agreement.
	Revenue from product deliveries
	The Company recognizes revenue from the delivery of its products when delivery has occurred, title has transferred, the selling price is fixed or determinable, collectability is reasonably assured and the Company has no further performance obligations. In addition, revenue is only recognized when the right of return no longer exists (which is the earlier of the product being dispensed through patient prescriptions or the expiration of the right of return) or when product returns can be reasonably estimated. Prior to October 2012, revenue from products sold to the Company’s wholesale distributors and retail chains was recognized based on the amount of product sold through to the end consumer. Since October 2012, due to the Company’s ability to reasonably estimate and determine allowances for product returns, rebates and discounts, the Company has been recognizing DUEXIS and RAYOS revenue at the point of sale to wholesale pharmaceutical distributors and retail chains. The Company has been recognizing VIMOVO revenue at the point of sale, consistent with its revenue recognition of DUEXIS and RAYOS, given the availability of prior VIMOVO product return data.
	The Company anticipates revenues will continue to result from distribution, marketing, manufacturing and supply agreements with third parties in Europe and certain Asian, Latin American and other countries with respect to LODOTRA.
	Under the manufacturing and supply agreements with Mundipharma Medical Company (“Mundipharma Medical”), Mundipharma Medical agreed to purchase LODOTRA exclusively from the Company at a price based on a specified percentage of the average net selling price (“ANSP”) for sales in a given country, subject to a minimum price. Mundipharma Medical has a nine-month period from purchase date to request an ANSP adjustment. If the ANSP is lower than the actual purchase price, then Mundipharma Medical would receive a price adjustment. Products sold to Mundipharma Medical are recognized upon delivery at the minimum price, as no contractual right of return exists. The difference between the actual selling price and the minimum price is recorded as deferred revenue until such time as adjustments for product returns, rebates and discounts can be reliably estimated or the nine-month ANSP adjustment period passes, at which time any previously deferred revenue would be recognized as revenue. As of December 31, 2013 and 2012, deferred revenues related to the sale of LODOTRA were $615 and $1,939, respectively. Additionally, as of December 31, 2013 and 2012, deferred revenues related to milestone and upfront payments received under existing agreements were $8,682 and $8,175, respectively.
	In December 2011, the Company began recognizing revenues from the sale of DUEXIS following its commercial launch in the United States. DUEXIS is currently sold to wholesale pharmaceutical distributors and to several national and regional retail chains. Until the Company could reliably estimate returns, the Company determined that shipment of products to wholesale pharmaceutical distributors and regional retail chains did not meet the criteria for revenue recognition at the time of shipment. The Company therefore deferred DUEXIS revenue recognition until the right of return no longer existed, which was the earlier of DUEXIS being dispensed through patient prescriptions or the expiration of the right of return (twelve months after the expiration date of the product).
	During the fourth quarter of 2012, the Company changed from recognizing DUEXIS revenue upon product being dispensed through patient prescriptions to recognizing revenue when product is sold into the wholesale pharmaceutical distributor and retail chain channel. This change was based on approximately one year of minimal product return quantities and an enhanced ability and historical experience upon which to monitor DUEXIS inventory levels in the distribution channel and to assess the relative risk of potential product returns. The Company believes it has the ability to reliably estimate returns and therefore recognizes revenue on the sale of DUEXIS, RAYOS and VIMOVO at the point of sale to the wholesaler.
Product Sales Discounts and Allowances	'
	Product Sales Discounts and Allowances
	Prior to the fourth quarter of 2012, the Company recorded DUEXIS sales to wholesale pharmaceutical distributors and retail chains as deferred revenue. Allowances for product returns, rebates and discounts were also deferred at the time of sale to wholesale pharmaceutical distributors and national and regional retail chains. These deferred expenses were recognized to arrive at net product sales at the time the related revenue was recognized. In the fourth quarter of 2012, the Company began recognizing revenue at the point of sale to its wholesale pharmaceutical distributors and retail chains, at which point the associated allowances for product returns, rebates and allowances were also recognized. The Company is required to make significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the Company will be required to make adjustments to these allowances in the future. In connection with its marketing of VIMOVO in the United States, the Company has been recognizing VIMOVO revenue at the point of sale to its wholesale pharmaceutical distributors and retail chains.
	Customer Discounts and Rebates
	Product Launch Discounts
	The Company has offered additional discounts to wholesale distributors for product purchased at the time of product launch. The Company has recorded these discounts as an allowance against accounts receivable and a reduction of revenue when orders were placed.
	Customer Rebates
	The Company participates in certain commercial rebate programs. Under these rebate programs, the Company pays a rebate to the commercial entity or third-party administrator of the program. The Company accrues estimated rebates based on contract prices, estimated percentages of product sold to qualified patients and estimated levels of inventory in the distribution channel and records the rebate as a reduction of revenue.
	Distribution Service Fees
	The Company includes distribution service fees paid to its wholesalers for distribution and inventory management services as a reduction to revenue. The estimates are based on contractually determined fees, typically as a percentage of revenue.
	Government Rebates and Chargebacks
	Government Rebates
	The Company participates in certain federal government rebate programs, such as Medicare and Medicaid. The Company accrues estimated rebates based on percentages of product sold to qualified patients, estimated rebate percentages and estimated levels of inventory in the distribution channel that will be sold to qualified patients and records the rebate as a reduction of revenue.
	Government Chargebacks
	The Company provides discounts to federal government qualified entities with whom the Company has contracted. These federal entities purchase products from the wholesale pharmaceutical distributors at a discounted price, and the wholesale pharmaceutical distributors then charge back to the Company the difference between the current retail price and the contracted price that the federal entities paid for the products. The Company accrues estimated chargebacks based on contract prices and sell-through sales data obtained from third party information and records the chargeback as a reduction of revenue.
	Co-Pay Assistance
	The Company offers discount card programs to patients under which the patient receives a discount on his or her prescription. The Company reimburses pharmacies for this discount through a third-party vendor. The Company records the total amount of estimated discounts for sales recorded in the period as a reduction of revenue.
	Returns and Prompt Pay Allowances
	Sales Returns
	Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the product expiration date. Generally, product may be returned for a period beginning six months prior to its expiration date and up to one year after its expiration date. The right of return expires on the earlier of one year after the product expiration date or the time that the product is dispensed to the patient. The majority of product returns result from product dating, which falls within the range set by the Company’s policy, and are settled through the issuance of a credit to the customer. The estimate of the provision for returns is based upon the Company’s historical experience with actual returns, which is applied to the level of sales for the period that corresponds to the period during which the customer may return product. This period is known to the Company based on the shelf life of products at the time of shipment. The Company records sales returns as an allowance against accounts receivable and a reduction of revenue.
	Prompt Pay Discounts
	As an incentive for prompt payment, the Company offers a 2% cash discount to customers. The Company expects that all customers will comply with the contractual terms to earn the discount. The Company records the discount as an allowance against accounts receivable and a reduction of revenue.
Bad Debt Expense	'
	Bad Debt Expense
	The Company’s products are sold to wholesale distributors and retail chains through manufacturing and supply agreements. For the years ended December 31, 2013, 2012 and 2011, the Company did not experience a bad debt expense related to its accounts receivable balances. Accordingly, the Company has not established a reserve for bad debt expense. The Company will continue to monitor its accounts receivable balances to determine the impact, if any, of such factors as changes in customer concentration, credit risk and the realizability of its accounts receivable would require a bad debt reserve allowance in subsequent periods.
Cost of Goods Sold	'
	Cost of Goods Sold
	The Company recognizes cost of goods sold in connection with its sale of DUEXIS and RAYOS.
	Cost of goods sold of DUEXIS includes all costs directly related to the acquisition of product from the Company’s third party manufacturers, including freight charges and costs of distribution.
	Cost of goods sold of RAYOS includes all costs directly related to the acquisition of product from the Company’s third party manufacturers, including freight charges, amortization of developed technology, royalty payments to third parties for the use of certain licensed patents and applicable taxes.
	Until the Company began recognizing revenue at the point of sale of DUEXIS to the wholesaler in the fourth quarter of 2012, it also deferred the related DUEXIS cost of goods sold and recorded such amounts as other current assets until revenue was recognized.
	Cost of goods sold of LODOTRA includes raw material costs, costs associated with third parties who manufacture LODOTRA for the Company, supply chain costs, manufacturing overhead costs, amortization of developed technology, royalty payments to third parties for the use of certain licensed patents and applicable taxes.
	Cost of goods sold for VIMOVO in the fourth quarter of 2013, following our acquisition in November 2013 of certain assets and rights necessary to commercialize VIMOVO in the United States, includes only intangible amortization expense. Beginning in 2014, in connection with the Company’s marketing of VIMOVO in the United States, cost of goods sold for VIMOVO will include all costs directly related to the acquisition of product from AstraZeneca and/or the third-party manufacturer.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market value. Inventories consist of raw materials, work-in-process and finished goods. The Company has entered into manufacturing and supply agreements for the manufacture or purchase of raw materials and production supplies. The Company’s inventories include the direct purchase cost of materials and supplies and manufacturing overhead costs. As of December 31, 2013 and December 31, 2012, the Company had inventories of $8,701 and $5,245, respectively.
	Inventories exclude product sample inventory, which is included in other current assets and is expensed as a component of sales and marketing expense when provided to physicians or healthcare providers. As of December 31, 2013 and 2012, the Company had product sample inventory of $1,323 and $875, respectively.
Preclinical Studies and Clinical Trial Accruals	'
	Preclinical Studies and Clinical Trial Accruals
	The Company’s preclinical studies and clinical trials have historically been conducted by third-party contract research organizations and other vendors. Preclinical study and clinical trial expenses are based on the services received from these contract research organizations and vendors. Payments depend on factors such as the milestones accomplished, successful enrollment of certain numbers of patients and site initiation. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly. To date, the Company has had no significant adjustments to accrued clinical expenses.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. For the periods presented, the Company’s potential dilutive shares, which include shares issuable upon the exercise of outstanding stock options, unvested restricted stock units and warrants to purchase common stock, have not been included in the computation of diluted net loss per share for the periods presented in which there is a net loss as the result would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents primarily consist of cash balances and money market funds. Cash and cash equivalents were $80,480 and $104,087 as of December 31, 2013 and 2012, respectively. The Company’s policy is to invest excess cash in money market funds, which are generally of a short-term duration based upon operating requirements.
Restricted Cash	'
	Restricted Cash
	Restricted cash consists of balances included in interest-bearing money market accounts required by a vendor for the Company’s sponsored employee credit card program and by the lessor for the Company’s corporate office. As of December 31, 2013 and 2012, the Company had restricted cash in the amount of $738 and $800, respectively.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The estimated fair value of the Company’s derivative liability related to the convertible portion of its 5.00% Convertible Senior Notes due 2018 (the “Convertible Senior Notes”) was derived utilizing the binomial lattice approach for the valuation of convertible instruments. Assumptions used in the calculation included, among others, determining the appropriate credit spread using benchmarking analysis and solving for the implied credit spread, calculating the fair value of the stock component using a discounted risk free rate and borrowing cost and calculating the fair value of the note component using a discounted credit adjusted discount rate. Based on the assumptions used to determine the fair value of the derivative liability associated with the Convertible Senior Notes, the Company concluded that these inputs were Level 3 inputs. The Company will continue to derive the fair value of the derivative liability using the binomial lattice approach and these assumptions in all future reporting periods.
Business Combinations	'
	Business Combinations
	The Company accounts for business combinations in accordance with the pronouncement guidance in ASC 805, Business Combinations, in which acquired assets and liabilities are measured at their respective estimated fair values as of the acquisition date. The Company may be required, as in the case of intangible assets, contingent royalties or derivatives, to determine the fair value associated with these amounts by estimating the fair value using an income approach under the discounted cash flow method, which may include revenue projections and other assumptions made by the Company to determine the fair value.
Property and Equipment, Net	'
	Property and Equipment, Net
	Property and equipment are stated at cost less accumulated depreciation. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets for financial reporting purposes and an accelerated method for income tax reporting purposes. Upon retirement or sale of an asset, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repair and maintenance costs are charged to expenses as incurred and improvements are capitalized.
	Leasehold improvements are amortized on a straight-line basis over the term of the applicable lease, or the useful life of the assets, whichever is shorter.
	Depreciation and amortization periods for the Company’s property and equipment are as follows:
	Machinery and equipment	5-7 years
	Furniture and fixtures	3-5 years
	Computer equipment	3 years
	Software	3 years
	Trade show equipment	3 years
	Software includes internal-use software acquired and modified to meet the Company’s internal requirements. Amortization commences when the software is ready for its intended use.
Intangible Assets	'
	Intangible Assets
	The Company’s intangible assets consist of developed technology related to three of its approved products: LODOTRA outside the United States, RAYOS in the United States and intellectual property rights related to the Company’s acquisition of the U.S. rights to VIMOVO. The Company amortizes the LODOTRA and RAYOS intangible assets over twelve years, which is the estimated useful life of the underlying patents, and amortizes the U.S. intellectual property rights of the VIMOVO intangible asset over an estimated useful life of 61.5 months. The Company reviews its intangible assets when events or circumstances may indicate that the carrying value of these assets exceeds their fair value. The Company measures fair value based on the estimated future discounted cash flows associated with these assets in addition to other assumptions and projections that the Company deems to be reasonable and supportable.
Research and Development Expenses	'
	Research and Development Expenses
	Research and development expenses include, but are not limited to, payroll and other personnel expenses, consultant expenses, expenses incurred under agreements with contract research organizations to conduct clinical trials and expenses incurred to manufacture clinical trial materials.
Sales and Marketing Expenses	'
	Sales and Marketing Expenses
	Sales and marketing expenses consist principally of payroll of sales representatives and marketing and support staff, travel and other personnel-related expenses, marketing materials and distributed sample inventories. With the full commercial launch of RAYOS in the United States in late January 2013, the Company determined that costs related to medical affairs, which consist of expenses related to scientific publications, health outcomes, biostatistics, medical education and information, and medical communications, should be charged to sales and marketing expenses as incurred in accordance with GAAP. Prior to the full commercial launch of RAYOS, these medical affairs expenses were classified as research and development expenses.
Concentration of Credit Risk and Other Risks and Uncertainties	'
	Concentration of Credit Risk and Other Risks and Uncertainties
	Financial instruments that may potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. The Company’s cash and cash equivalents are invested in deposits with various banks in the United States, Switzerland and Germany that management believes are creditworthy. At times, deposits in these banks may exceed the amount of insurance provided on such deposits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents.
	The Company’s LODOTRA sales contracts are principally denominated in Euros and, therefore, its revenues are subject to significant foreign currency risk.
	To achieve profitable operations, the Company must successfully develop, obtain regulatory approval for, manufacture and market its products and product candidates, and/or acquire or in-license products from third parties. There can be no assurance that any additional products can be developed, will be approved for marketing by the regulatory authorities, or can be manufactured at an acceptable cost and with appropriate performance characteristics or that any new or existing products can be successfully marketed, acquired or in-licensed by the Company. These factors could have a material adverse effect on the Company’s operations.
	The Company relies on third parties to manufacture its commercial supplies of DUEXIS, VIMOVO and RAYOS/LODOTRA. The commercialization of any of its products or product candidates could be stopped, delayed or made less profitable if those third parties fail to provide the Company with sufficient quantities of product or fail to do so at acceptable quality levels or prices.
	The Company is required to maintain compliance with applicable Swiss laws with respect to its Swiss subsidiary, Horizon Pharma AG, including laws requiring maintenance of equity in the subsidiary to avoid overindebtedness, which requires Horizon Pharma AG to maintain assets in excess of its liabilities. The Company reviews on a regular basis whether its Swiss subsidiary is overindebted. As of December 31, 2013 and 2012, the Company’s Swiss subsidiary was overindebted, primarily as a result of operating losses at the subsidiary. The Company will continue to monitor and review steps to address any overindebtedness until such time as its Swiss subsidiary may generate positive income at a statutory level, which could require the Company to have cash at its Swiss subsidiary in excess of its near term operating needs and could affect the Company’s ability to have sufficient cash at its U.S. subsidiary to meet its near term operating needs. As of December 31, 2013 and 2012, Horizon Pharma AG had cash and cash equivalents of $3,476 and $4,708, respectively. Based upon the cash and cash equivalents held by Horizon Pharma AG as of December 31, 2013 and 2012 and Horizon Pharma AG’s level of overindebtedness at such time, the Company does not expect that its financial position or results of operations will be materially affected by any need to address overindebtedness at its Swiss subsidiary. To date, the overindebtedness of the Company’s Swiss subsidiary has not resulted in the need to divert material cash resources from its U.S. subsidiary.
	Historically, the Company’s accounts receivable balances have been highly concentrated with a select number of customers, consisting primarily of large wholesale pharmaceutical distributors who, in turn, sell the products to pharmacies, hospitals and other customers. For the year ended December 31, 2013, the Company’s top five customers, AmerisourceBergen, McKesson Corporation, Cardinal Health, Inc., Mundipharma and Rochester Drug Company, accounted for approximately 89% of total consolidated gross sales. For the year ended December 31, 2012, the Company’s top three customers, Mundipharma, McKesson Corporation and Cardinal Health, Inc., accounted for approximately 83% of total consolidated gross sales. In addition, four customers, McKesson Corporation, AmerisourceBergen, Rochester Drug Company and Cardinal Health, Inc., accounted for approximately 85% of the Company’s total outstanding accounts receivable balances at December 31, 2013. As of December 31, 2012, three customers, Cardinal Health, Inc., Walgreen Company and McKesson Corporation, accounted for approximately 77% of the Company’s total outstanding accounts receivable balances. Historically, the Company has not experienced any losses related to its accounts receivable balances.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss) (“OCI”). OCI includes certain changes in stockholders’ equity that are excluded from net income (loss), which consist of foreign currency translation adjustments. In February 2013, the Company adopted on a prospective basis FASB Accounting Standards Update 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). ASU 2013-02 requires an entity to report the effect of significant reclassifications out of accumulated OCI on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. As of December 31, 2013 and 2012, accumulated other comprehensive loss was $2,403 and $3,372, respectively.

The_Company_Tables

The Company (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Selected Line Items from Financial Statements Illustrating Effect of Revision	'
	The following table includes selected line items from our financial statements illustrating the effect of the revision:
		As Reported			Adjustment			As Revised
		(in thousands)
	Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2012
	Sales discounts and allowances		(384	)		(38	)		(422	)
	Net Sales		2,523			(38	)		2,485
	Cost of goods sold		2,067			(38	)		2,029
	Consolidated Statements of Comprehensive Loss for the Three Months Ended June 30, 2012
	Sales discounts and allowances		(767	)		(160	)		(927	)
	Net Sales		3,841			(160	)		3,681
	Cost of goods sold		2,855			(160	)		2,695
	Consolidated Statements of Comprehensive Loss for the Three Months Ended September 30, 2012
	Sales discounts and allowances		(790	)		(202	)		(992	)
	Net Sales		6,521			(202	)		6,319
	Cost of goods sold		3,810			(202	)		3,608
	Consolidated Statements of Comprehensive Loss for the Three Months Ended December 31, 2012
	Sales discounts and allowances		(1,405	)		(388	)		(1,793	)
	Net Sales		6,747			(388	)		6,359
	Cost of goods sold		3,931			(388	)		3,543
	Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2013
	Sales discounts and allowances		(1,527	)		(478	)		(2,005	)
	Net Sales		9,171			(478	)		8,693
	Cost of goods sold		4,247			(478	)		3,769
	Consolidated Statements of Comprehensive Loss for the Three Months Ended June 30, 2013
	Sales discounts and allowances		(5,383	)		(1,123	)		(6,506	)
	Net Sales		12,254			(1,123	)		11,131
	Cost of goods sold		3,517			(1,123	)		2,394
	Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2013
	Sales discounts and allowances		(6,910	)		(1,601	)		(8,511	)
	Net Sales		21,425			(1,601	)		19,824
	Cost of goods sold		7,764			(1,601	)		6,163
	Consolidated Statements of Comprehensive Loss for the Three Months Ended September 30, 2013
	Sales discounts and allowances		(5,306	)		(2,106	)		(7,412	)
	Net Sales		26,218			(2,106	)		24,112
	Cost of goods sold		5,313			(2,106	)		3,207
	Consolidated Statements of Comprehensive Loss for the Nine Months Ended September 30, 2013
	Sales discounts and allowances		(12,216	)		(3,707	)		(15,923	)
	Net Sales		47,643			(3,707	)		43,936
	Cost of goods sold		13,077			(3,707	)		9,370

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Depreciation and Amortization Periods for Property and Equipment	'
	Depreciation and amortization periods for the Company’s property and equipment are as follows:
	Machinery and equipment	5-7 years
	Furniture and fixtures	3-5 years
	Computer equipment	3 years
	Software	3 years
	Trade show equipment	3 years

Business_Acquisition_Tables

Business Acquisition (Tables)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Fair Values Assigned to Assets Acquired and Liabilities Assumed	'
	The following table shows the fair values assigned to the assets acquired and liabilities assumed by the Company as part of the asset purchase agreement:
		Allocation
	Samples inventory	$	287
	VIMOVO intellectual property		67,705
	Contingent royalty liabilities		(32,992	)
	Total cash consideration paid	$	35,000
Consolidated Pro Forma Financial Information	'
	Additionally, the following table sets forth unaudited financial information and has been compiled from historical financial statements and other information, but is not necessarily indicative of the results that actually would have been achieved had the transactions occurred on the dates indicated or that may be achieved in the future.
		For the Years Ended December 31,
		2013								2012
		As reported			Pro-forma		Pro-forma			As			Pro-forma			Pro-forma
					adjustments		(Unaudited)			reported			adjustments			(Unaudited)
					(Unaudited)								(Unaudited)
	Net revenues	$	74,016		$	20,379	$	94,395		$	18,844		$	25,195		$	44,039
	Net income (loss)		(149,005	)		14,464		(134,541	)		(87,794	)		(38,793	)		(126,587	)
	Loss per share: Basic and diluted	$	(2.34	)	$	0.23	$	(2.11	)	$	(2.26	)	$	(1.00	)	$	(3.26	)

Earnings_per_Share_Tables

Earnings per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Basic and Diluted Earnings (Loss) per Share	'
	The following table presents basic and diluted earnings (loss) per share for the years ended December 31, 2013, 2012 and 2011 as follows:
		For the Years Ended December 31,
		2013			2012			2011
	Basic and diluted earnings per share calculation:
	Net loss	$	(149,005	)	$	(87,794	)	$	(113,265	)
	Weighted average of common shares outstanding		63,657,924			38,871,422			9,014,968
	Basic and diluted net loss per share	$	(2.34	)	$	(2.26	)	$	(12.56	)

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Components of Inventories	'
	The components of inventories as of December 31, 2013 and 2012 consisted of the following:
		As of December 31,
		2013		2012
	Raw materials	$	91	$	40
	Work-in-process		522		824
	Finished goods		8,088		4,381
	Net inventories	$	8,701	$	5,245

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Prepaid Expenses and Other Current Assets	'
	Prepaid expenses and other current assets as of December 31, 2013 and 2012 consisted of the following:
		As of December 31,
		2013		2012
	Product samples inventory	$	1,323	$	875
	Prepaid software license fees		855		—
	Prepaid clinical trial studies		688		661
	Prepaid co-pay expenses		621		—
	Prepaid marketing expenses		381		607
	Prepaid insurance		379		265
	Prepaid FDA product and manufacturing fees		312		139
	Other prepaid expenses		329		745
	Other current assets		—		31
	Total prepaid and other current assets	$	4,888	$	3,323

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	Property and equipment as of December 31, 2013 and 2012 consisted of the following:
		As of December 31,
		2013			2012
	Machinery and equipment	$	2,367		$	2,248
	Furniture and fixtures		113			116
	Computer equipment		2,160			1,211
	Software		775			646
	Trade show equipment		228			228
	Leasehold improvement		783			783
			6,426			5,232
	Less-accumulated depreciation		(2,646	)		(1,507	)
	Total property and equipment	$	3,780		$	3,725

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	As of December 31, 2013 and 2012, intangible assets consisted of the following:
		December 31, 2013										December 31, 2012
		Cost		Accumulated			Currency			Net Book		Cost		Accumulated			Currency			Net Book
		Basis		Amortization			Translation			Value		Basis		Amortization			Translation			Value
	Developed technology	$	84,779	$	(17,823	)	$	(2,136	)	$	64,820	$	84,779	$	(11,118	)	$	(4,769	)	$	68,892
	VIMOVO intellectual property		67,705		(1,431	)		—			66,274		—		—			—			—
	Total intangible assets	$	152,484	$	(19,254	)	$	(2,136	)	$	131,094	$	84,779	$	(11,118	)	$	(4,769	)	$	68,892
Estimated Future Amortization Expense	'
	Amortization expense of the Company’s developed technology for the years ended December 31, 2013, 2012 and 2011 was $8,137, $4,732 and $3,753, respectively. As of December 31, 2013, estimated future amortization expense was as follows:
	2014	$	19,906
	2015		19,906
	2016		19,906
	2017		19,906
	2018 and thereafter		51,471
	Total	$	131,094

Other_Assets_Tables

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Other Assets	'
	Other assets as of December 31, 2013 and 2012, consisted of the following:
		As of December 31,
		2013		2012
	Deferred financing costs	$	6,268	$	3,195
	Long-term clinical study deposits		114		661
	Long-term inventory deposits		479		505
	Other		96		88
	Total other assets	$	6,957	$	4,449

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Accrued Liabilities	'
	Accrued liabilities as of December 31, 2013 and 2012, consisted of the following:
		As of December 31,
		2013		2012
	Payroll related expenses	$	9,491	$	6,290
	Accrued trade discounts and rebates		8,463		2,704
	Sales and marketing expenses		1,761		1,265
	Accrued interest		810		2,538
	Deferred rent		755		876
	Clinical and regulatory expenses		488		652
	Professional services		350		399
	Contract manufacturing expenses		301		1,094
	Consulting services		283		228
	Accrued other		1,347		738
	Total accrued liabilities	$	24,049	$	16,784

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Assets and Liabilities at Fair Value on Recurring Basis	'
	The following table sets forth the Company’s financial assets and liabilities at fair value on a recurring basis as of December 31, 2013 and 2012:
		2013
		Level 1			Level 2			Level 3		Total
	Assets:
	Money market funds	$	66,817		$	—		$	—	$	66,817
	Total assets at fair value	$	66,817		$	—		$	—	$	66,817
	Liabilities:
	Derivative liability	$	—		$	—		$	109,410	$	109,410
	Total liabilities at fair value	$	—		$	—		$	109,410	$	109,410
		2012
		Level 1			Level 2			Level 3		Total
	Assets:
	Money market funds	$	97,670		$	—		$	—	$	97,670
	Total assets at fair value	$	97,670		$	—		$	—	$	97,670
Assumptions used to Determine Initial Fair Value and Fair Value of Conversion Option Embedded in Convertible Senior Notes	'
	The following table presents the assumptions used by the Company to determine the initial fair value and the fair value as of December 31, 2013 of the conversion option embedded in the Convertible Senior Notes:
		November 18,			December 31,
		2013			2013
	Stock price	$	4.47		$	7.62
	Risk free rate		1.33	%		1.69	%
	Borrowing cost		5.0% and 3.5	%		5.0% and 3.5	%
	Weights		Equal weight			Equal weight
	Credit spread (in basis points)		1,030 and 1,170			930 and 1,170
	Volatility		40	%		40	%
	Initial conversion price	$	5.36		$	5.36
	Remaining time to maturity (in years)		5			4.9

Debt_Agreements_Tables

Debt Agreements (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Outstanding Debt Balances	'
	The Company’s outstanding debt balances as of December 31, 2013 and 2012, consisted of the following:
		As of December 31,
		2013			2012
	Convertible Senior Notes	$	150,000		$	—
	Senior Secured Loan		—			61,843
	Current debt maturities		—			(11,935	)
	Debt discount		(39,238	)		(13,042	)
	Long-term debt, net of current maturities	$	110,762		$	36,866

Equity_Incentive_Plans_Tables

Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Stock Options Activity	'
	The following table summarizes stock options activity under the 2011 EIP for the year ended December 31, 2013 as follows:
		Options			Weighted		Weighted Average		Aggregate
					Average		Remaining		Intrinsic Value
					Exercise  Price		Contractual Term		(in thousands)
	Outstanding as of December 31, 2012		2,746,918		$	8.85
	Granted		2,158,950		$	2.84
	Exercised		(41,820	)	$	3.88
	Forfeited		(452,968	)	$	3.88
	Outstanding as of December 31, 2013		4,411,080		$	6.47		7.9 years	$	13,283
	Exercisable as of December 31, 2013		2,079,728		$	9.57		6.8 years	$	3,860
Summary of Outstanding Stock Options	'
	The following table summarizes the Company’s outstanding stock options at December 31, 2013:
		Options Outstanding							Options Exercisable
	Exercise Price Ranges	Number of options			Weighted		Weighted		Number		Weighted
		outstanding			Average		Average		Exercisable		Average
					Exercise Price		Remaining				Exercise
							Contractual				Price
							Term
	$1.36 - $3.97		2,079,203		$	2.63		9.1 years		432,699	$	2.65
	$4.10 - $5.20		1,039,318			4.98		7.5 years		651,196		5.02
	$7.48 - $12.94		935,627			10.04		7.0 years		645,136		11.01
	$13.47 - $17.22		106,568			13.91		5.6 years		104,547		13.85
	$20.78 - $28.83		250,364			28.05		651 years		246,150		28.18
			4,411,080		$	6.47		7.9 years		2,079,728	$	9.57
Weighted Average Fair Value per Share of Stock Option Awards Granted and Assumptions Used to Value Stock Options	'
	The weighted average fair value per share of stock option awards granted during the years ended December 31, 2013, 2012 and 2011, and assumptions used to value stock options, are as follows:
		For the Years Ended Deceber 31,
		2013			2012		2011
	Dividend yield		—			—		—
	Risk-free interest rate		1.20%			1.00%		1.20%
	Weighted average volatility		86.70%			89.00%		89.30%
	Expected life (in years)		5.98			5.96		6
	Weighted average grant date fair value per share of options granted	$	2.8		$	2.5	$	4.2
Summary of Restricted Stock Unit Activity	'
	The following table summarizes restricted stock unit activity for the year ended December 31, 2013 as follows:
		Number			Weighted Average
		of Units			Grant-Date Fair
					Value Per Units
	Outstanding as of December 31, 2012		232,158		$	4.92
	Granted		831,004		$	2.95
	Vested		(174,213	)	$	6.05
	Forfeited		(55,948	)	$	2.86
	Outstanding as of December 31, 2013		833,001		$	2.86
Summary of Share-Based Compensation Expense	'
	The following table summarizes share-based compensation expense included in the Company’s consolidated statements of operations for the years ended December 31, 2013, 2012 and 2011:
		For the Years Ended December 31,
		2013			2012		2011
	Share-based compensation expense:
	Research and development	$	1,054		$	1,186	$	760
	Sales and marketing		1,465			1,090		451
	General and administrative		2,495			2,385		1,319
	Net effect of share-based compensation expense on net loss	$	5,014		$	4,661	$	2,530

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Components of Benefit for Income Taxes	'
	The components of the benefit for income taxes were as follows for the years ended December 31, 2013, 2012 and 2011:
			For the Years Ended December 31,
			2013			2012			2011
	Current provision
	Federal		$	—		$	—		$	—
	State			4			4			3
	Foreign			43			35			28
	Total current provision			47			39			31
	Deferred benefit
	Federal			—			—			—
	State			—			—			—
	Foreign			(1,168	)		(5,210	)		(14,714	)
	Total deferred benefit			(1,168	)		(5,210	)		(14,714	)
	Total benefit for income taxes		$	(1,121	)	$	(5,171	)	$	(14,683	)
Company's of Loss Before Benefit for Income Taxes	'
	The Company’s loss before benefit for income taxes by jurisdiction for the years ended December 31, 2013, 2012 and 2011 is as follows:
			For the Years Ended December 31,
			2013			2012			2011
	United States		$	(139,347	)	$	56,038		$	(43,148	)
	International			(10,779	)		(149,003	)		(84,800	)
	Loss before benefit for income taxes		$	(150,126	)	$	(92,965	)	$	(127,948	)
Reconciliation Between Statutory Federal Income Tax and Effective Tax	'
	A reconciliation between the statutory federal income tax and the Company’s effective tax is as follows:
			For the Years Ended December 31,
			2013			2012			2011
	U.S. federal income taxes at statutory tax rate		$	(52,543	)	$	(32,538	)	$	(44,781	)
	Stock based compensation			1,107			1,063			658
	Foreign tax rate differential			2,019			4,376			14,994
	Deferred taxes not benefited			23,921			21,715			14,499
	Derivative liability			24,255			—			—
	Research and development credit			120			(5	)		(79	)
	Other			—			218			26
	Effective income taxes		$	(1,121	)	$	(5,171	)	$	(14,683	)
Deferred Tax Assets and Liabilities	'
	The tax effects of the temporary differences and net operating losses that give rise to significant portions of deferred tax assets and liabilities are as follows:
			As of December 31,
			2013			2012			2011
	Deferred tax assets:
	Net operating loss carryforwards		$	121,001		$	97,724		$	68,689
	Derivative liability			14,799			—			—
	Accruals and reserves			7,073			5,144			1,906
	Original issuance discount related to capped call			6,740			—			—
	Contingent royalties			3,122			—			—
	Research and development credits			2,571			2,445			2,447
	Foreign intangible assets			63			76			90
	Total deferred tax assets			155,369			105,389			73,132
	Valuation allowance			(128,422	)		(95,970	)		(68,194	)
	Deferred tax assets, net of valuation allowance			26,947			9,419			4,938
	Deferred tax liabilities:
	Debt discount		$	14,477		$	—		$	—
	In-process research and development			—			—			7,354
	Developed technology			13,009			13,827			7,145
	Intangible assets			2,823			—			—
	Total deferred tax liabilities			30,309			13,827			14,499
	Net deferred income tax liability		$	3,362		$	4,408		$	9,561
Reconciliation of Beginning and Ending Amounts of Valuation Allowance	'
	A reconciliation of the beginning and ending amounts of the valuation allowance for the years ended December 31, 2013, 2012 and 2011 were as follows:
	Valuation allowance at December 31, 2010		$	(53,981	)
	Increase for current year activity			(14,213	)
	Valuation allowance at December 31, 2011		$	(68,194	)
	Increase for current year activity			(32,034	)
	Release in valuation allowance (1)			4,258
	Valuation allowance at December 31, 2012		$	(95,970	)
	Increase for current year activity			(32,452	)
	Valuation allowance at December 31, 2013		$	(128,422	)
	-1	In connection with the FDA approval of RAYOS on July 26, 2012, the Company reclassified its indefinite-lived IPR&D intangible asset to a finite-lived developed technology intangible asset and began amortizing the asset to cost of goods during the third quarter of 2012. The reclassification to developed technology required the Company to reassess its deferred tax positions, which indicated that it was more likely than not that a greater portion of the Company’s deferred tax assets would be realized as a result of the reclassification of its intangible asset from indefinite-lived to finite-lived. As a result of this assessment, the Company reduced its deferred tax asset valuation allowances, which resulted in a corresponding reduction to the Company’s net deferred tax liabilities and the recognition of a one-time net income tax benefit of $4,258 that was recorded as an additional benefit for income taxes during the third quarter of 2012.
Changes in Uncertain Income Tax Positions	'
	The changes in the Company’s uncertain income tax positions for the years ended December 31, 2013, 2012 and 2011 consisted of the following:
			For the Years Ended December 31,
			2013			2012			2011
	Beginning balance		$	442		$	442		$	424
	Tax positions related to current year:
	Additions			51			2			34
	Reductions			—			—			—
				51			2			34
	Tax positions related to prior years:
	Additions			—			—			—
	Reductions			(2	)		(2	)		(16	)
	Settlements			—			—			—
	Lapses in statutes of limitations			—			—			—
	Additions from current year acquisitions			—			—			—
				(2	)		(2	)		(16	)
	Ending balance		$	491		$	442		$	442

Selected_Quarterly_Financial_I1

Selected Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary of Selected Financial Results of Operations	'
	The following table provides a summary of selected financial results of operations by quarter for the years ended December 31, 2013 and 2012 as follows:
	2013		First			Second			Third			Fourth
	Net sales (1)		$	8,693		$	11,131		$	24,112		$	30,080
	Gross profit			4,924			8,737			20,905			24,825
	Loss from operations			(18,544	)		(15,804	)		(2,744	)		(5,762	)
	Net loss			(22,171	)		(18,441	)		(5,492	)		(102,901	)
	Net loss per common share-basic and diluted		$	(0.36	)	$	(0.29	)	$	(0.08	)	$	(1.56	)
	2012		First			Second			Third			Fourth
	Net sales (1)		$	2,485		$	3,681		$	6,319		$	6,359
	Gross profit			456			986			2,711			2,816
	Loss from operations			(19,788	)		(18,345	)		(18,714	)		(22,026	)
	Net loss			(23,726	)		(22,782	)		(16,953	)		(24,333	)
	Net loss per common share-basic and diluted		$	(0.98	)	$	(0.68	)	$	(0.47	)	$	(0.40	)
	-1	The net sales amounts listed above for the First, Second and Third quarters of 2013 have been revised from $9,171, $12,254 and $26,218, respectively, and the net sales amounts listed above for the First, Second, Third and Fourth quarters of 2012 have been revised from $2,523, $3,842, $6,520 and $6,747, respectively, reflecting the reclassification of wholesaler service fees from cost of goods sold to sales discounts and allowances. See Note 1 “The Company” in the notes to the Company’s consolidated financial statements included in this Annual Report on Form 10-K.

The_Company_Additional_Informa

The Company - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2011	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2010
	Employee	Employee	Employee	Employee	Employee
Basis Of Presentation [Line Items]	'	'	'	'	'	'	'
Number of sales representatives	115	290	150	80	250	'	'
Overlap of physician targets	'	'	'	'	30.00%	'	'
Cash and cash equivalents	'	$104,087	'	'	$80,480	$17,966	$5,384
Minimum [Member]	'	'	'	'	'	'	'
Basis Of Presentation [Line Items]	'	'	'	'	'	'	'
Number of sales representatives	'	'	'	'	25	'	'
Maximum [Member]	'	'	'	'	'	'	'
Basis Of Presentation [Line Items]	'	'	'	'	'	'	'
Number of sales representatives	'	'	'	'	40	'	'
Rheumatology [Member]	'	'	'	'	'	'	'
Basis Of Presentation [Line Items]	'	'	'	'	'	'	'
Number of sales representatives	'	'	'	'	40	'	'

The_Company_Summary_of_Selecte

The Company - Summary of Selected Line Items from Financial Statements Illustrating Effect of Revision (Detail) (USD $)	3 Months Ended								6 Months Ended	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Jun. 30, 2013	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Sales discounts and allowances	'	($7,412)	($6,506)	($2,005)	($1,793)	($992)	($927)	($422)	($8,511)	($15,923)	($28,979)	($4,134)	($12)
Net sales	30,080	24,112	11,131	8,693	6,359	6,319	3,681	2,485	19,824	43,936	74,016	18,844	6,927
Cost of goods sold	'	3,207	2,394	3,769	3,543	3,608	2,695	2,029	6,163	9,370	14,625	11,875	7,267
As Reported [Member]	'	'	'	'	'	'	'	'	'	'	'	'	'
Sales discounts and allowances	'	-5,306	-5,383	-1,527	-1,405	-790	-767	-384	-6,910	-12,216	'	'	'
Net sales	'	26,218	12,254	9,171	6,747	6,521	3,841	2,523	21,425	47,643	'	'	'
Cost of goods sold	'	5,313	3,517	4,247	3,931	3,810	2,855	2,067	7,764	13,077	'	'	'
Adjustment [Member]	'	'	'	'	'	'	'	'	'	'	'	'	'
Sales discounts and allowances	'	-2,106	-1,123	-478	-388	-202	-160	-38	-1,601	-3,707	'	'	'
Net sales	'	-2,106	-1,123	-478	-388	-202	-160	-38	-1,601	-3,707	'	'	'
Cost of goods sold	'	($2,106)	($1,123)	($478)	($388)	($202)	($160)	($38)	($1,601)	($3,707)	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)

12 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Nov. 22, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Up Front Fee and Milestone Payment Arrangement [Member]

Up Front Fee and Milestone Payment Arrangement [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Convertible Senior Notes [Member]

Convertible Senior Notes [Member]

Lodotra [Member]

Lodotra [Member]

Other Current Assets [Member]

Other Current Assets [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Sales Revenue [Member]

Sales Revenue [Member]

Customer

Customer

Customer

Customer

Summary Of Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Foreign exchange gain (loss)

$1,206

$489

($1,023)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenues from sale

'

'

'

'

8,682

8,175

'

'

'

'

'

'

'

'

615

1,939

'

'

Cash discount to incentive for prompt payment

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Bad debt expense

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reserve for bad debt expense

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventories, net

8,701

5,245

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Product sample inventory

1,323

875

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,323

875

Cash and cash equivalents

80,480

104,087

17,966

5,384

'

'

3,476

4,708

'

'

'

'

'

'

'

'

'

'

Restricted cash

738

800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

11.22%

'

'

'

'

Useful life of intangible assets

'12 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of intangible asset period

'61 months 15 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of major customers for accounts receivable

'

'

'

'

'

'

'

'

5

3

'

'

'

'

'

'

'

'

Consolidated receivable/sales percentage to major customers

'

'

'

'

'

'

'

'

89.00%

83.00%

85.00%

77.00%

'

'

'

'

'

'

Number of major customers for sales revenues

'

'

'

'

'

'

'

'

'

'

4

3

'

'

'

'

'

'

Accumulated other comprehensive loss

($2,403)

($3,372)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Depreciation and Amortization Period for Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2013
Machinery and Equipment [Member] | Minimum [Member]	'
Summary Of Significant Accounting Policies [Line Items]	'
Depreciation and amortization	'5 years
Machinery and Equipment [Member] | Maximum [Member]	'
Summary Of Significant Accounting Policies [Line Items]	'
Depreciation and amortization	'7 years
Furniture and Fixtures [Member] | Minimum [Member]	'
Summary Of Significant Accounting Policies [Line Items]	'
Depreciation and amortization	'3 years
Furniture and Fixtures [Member] | Maximum [Member]	'
Summary Of Significant Accounting Policies [Line Items]	'
Depreciation and amortization	'5 years
Computer Equipment [Member]	'
Summary Of Significant Accounting Policies [Line Items]	'
Depreciation and amortization	'3 years
Software [Member]	'
Summary Of Significant Accounting Policies [Line Items]	'
Depreciation and amortization	'3 years
Trade Show Equipment [Member]	'
Summary Of Significant Accounting Policies [Line Items]	'
Depreciation and amortization	'3 years

Business_Acquisition_Additiona

Business Acquisition - Additional Information (Detail) (USD $)	12 Months Ended					1 Months Ended
	Dec. 31, 2013	Nov. 30, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Nov. 30, 2013	Nov. 30, 2013	Dec. 31, 2013	Dec. 31, 2013
			Royalty [Member]	Guaranteed [Member]	Contingent Royalties [Member]	Minimum [Member]	Maximum [Member]	2014 [Member]	Each Year [Member]
						Pozen License Agreement [Member]	Pozen License Agreement [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'
Business acquisition, asset purchase agreement date	18-Nov-13	'	'	'	'	'	'	'	'
One-time upfront cash payment	$35,000,000	'	'	'	'	'	'	'	'
Percentage of royalty on net sales	10.00%	'	'	'	'	'	'	'	'
Minimum annual royalty obligations	'	'	'	'	'	'	'	5,000,000	7,500,000
Annual aggregate global sales under license agreement	'	'	'	'	'	550,000,000	1,250,000,000	'	'
Amount payable based upon proportional sales	'	260,000,000	'	'	'	'	'	'	'
Supply agreement expire date	31-Dec-14	'	'	'	'	'	'	'	'
Acquisition date	22-Nov-13	'	'	'	'	'	'	'	'
Amortization of intangible asset period	'61 months 15 days	'	'	'	'	'	'	'	'
Fair value of royalty payments	$109,410,000	'	$33,000,000	$24,500,000	$8,500,000	'	'	'	'

Business_Acquisition_Fair_Valu

Business Acquisition - Fair Values Assigned to Assets Acquired and Liabilities Assumed (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Business Combinations [Abstract]	'
Samples inventory	$287
VIMOVO intellectual property	67,705
Contingent royalty liabilities	-32,992
Total cash consideration paid	$35,000

Business_Acquisition_Consolida

Business Acquisition - Consolidated Pro Forma Financial Information (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
As Reported [Member]	'	'
Business Acquisition [Line Items]	'	'
Net revenues	$74,016	$18,844
Net income (loss)	-149,005	-87,794
Loss per share: Basic and diluted	($2.34)	($2.26)
Pro-forma Adjustments [Member]	'	'
Business Acquisition [Line Items]	'	'
Net revenues	20,379	25,195
Net income (loss)	14,464	-38,793
Loss per share: Basic and diluted	$0.23	($1)
Pro-forma [Member]	'	'
Business Acquisition [Line Items]	'	'
Net revenues	94,395	44,039
Net income (loss)	($134,541)	($126,587)
Loss per share: Basic and diluted	($2.11)	($3.26)

Earnings_per_Share_Basic_and_D

Earnings per Share - Basic and Diluted Earnings (Loss) per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Basic and diluted earnings per share calculation:	'	'	'	'	'	'	'	'	'	'	'
Net loss	($102,901)	($5,492)	($18,441)	($22,171)	($24,333)	($16,953)	($22,782)	($23,726)	($149,005)	($87,794)	($113,265)
Weighted average of common shares outstanding	'	'	'	'	'	'	'	'	63,657,924	38,871,422	9,014,968
Basic and diluted net loss per share	'	'	'	'	'	'	'	'	($2.34)	($2.26)	($12.56)

Earnings_per_Share_Additional_

Earnings per Share - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Outstanding Common Stock Warrants [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Reconciliation of basic and diluted earnings per share	16,114,746	17,480,243	'
Stock Options [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Reconciliation of basic and diluted earnings per share	4,411,080	2,746,918	2,532,262
Unvested Restricted Stock Units [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Reconciliation of basic and diluted earnings per share	833,001	232,158	304,890
Vested Restricted Stock Units [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Reconciliation of basic and diluted earnings per share	101,004	225,000	'
Convertible Senior Notes [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Reconciliation of basic and diluted earnings per share	13,164,951	'	'

Inventories_Components_of_Inve

Inventories - Components of Inventory (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$91	$40
Work-in-process	522	824
Finished goods	8,088	4,381
Net inventories	$8,701	$5,245

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Prepaid Expenses And Other Current Assets [Line Items]	'	'
Product samples inventory	$1,323	$875
Prepaid insurance	379	265
Other prepaid expenses	329	745
Other current assets	'	31
Total prepaid and other current assets	4,888	3,323
Software License Fees [Member]	'	'
Prepaid Expenses And Other Current Assets [Line Items]	'	'
Prepaid expense	855	'
Research and Development [Member]	'	'
Prepaid Expenses And Other Current Assets [Line Items]	'	'
Prepaid expense	688	661
Co-Pay Expenses [Member]	'	'
Prepaid Expenses And Other Current Assets [Line Items]	'	'
Prepaid expense	621	'
Marketing Expenses [Member]	'	'
Prepaid Expenses And Other Current Assets [Line Items]	'	'
Prepaid expense	381	607
FDA Product and Manufacturing Fees [Member]	'	'
Prepaid Expenses And Other Current Assets [Line Items]	'	'
Prepaid expense	$312	$139

Property_and_Equipment_Propert

Property and Equipment - Property and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$6,426	$5,232
Less-accumulated depreciation	-2,646	-1,507
Total property and equipment	3,780	3,725
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	2,367	2,248
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	113	116
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	2,160	1,211
Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	775	646
Trade Show Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	228	228
Leasehold Improvement [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$783	$783

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property Plant And Equipment [Abstract]	'	'	'
Depreciation expense	$1,173	$806	$446

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jul. 26, 2012	Jul. 26, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'	'	'	'
Reclassification of asset	$35,456	$35,456	'	'	$0	'
Estimated fair value of IPR&D	'	'	36,638	'	'	36,638
Intangible impairment charge related to its IPR&D asset	'	'	69,621	'	'	69,621
Useful life of intangible assets	'	'	'	'12 years	'	'
Amortization expense of developed technology	'	'	'	$8,137	$4,732	$3,753

Intangible_Assets_Intangible_A

Intangible Assets - Intangible Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Cost Basis	$152,484	$84,779
Accumulated Amortization	-19,254	-11,118
Currency Translation	-2,136	-4,769
Net Book Value	131,094	68,892
Developed Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost Basis	84,779	84,779
Accumulated Amortization	-17,823	-11,118
Currency Translation	-2,136	-4,769
Net Book Value	64,820	68,892
VIMOVO Intellectual Property [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost Basis	67,705	'
Accumulated Amortization	-1,431	'
Net Book Value	$66,274	'

Intangible_Assets_Estimated_Fu

Intangible Assets - Estimated Future Amortization Expense (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'	'
2014	$19,906	'
2015	19,906	'
2016	19,906	'
2017	19,906	'
2018 and thereafter	51,471	'
Net Book Value	$131,094	$68,892

Other_Assets_Other_Assets_Deta

Other Assets- Other Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Other Assets Noncurrent [Abstract]	'	'
Deferred financing costs	$6,268	$3,195
Long-term clinical study deposits	114	661
Long-term inventory deposits	479	505
Other	96	88
Total other assets	$6,957	$4,449

Accrued_Liabilities_Accrued_Li

Accrued Liabilities - Accrued Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Payroll related expenses	$9,491	$6,290
Accrued trade discounts and rebates	8,463	2,704
Sales and marketing expenses	1,761	1,265
Accrued interest	810	2,538
Deferred rent	755	876
Clinical and regulatory expenses	488	652
Professional services	350	399
Contract manufacturing expenses	301	1,094
Consulting services	283	228
Accrued other	1,347	738
Total accrued liabilities	$24,049	$16,784

Fair_Value_Measurements_Assets

Fair Value Measurements - Assets and Liabilities at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities at fair value	$109,410	'
Fair Value Measurements, Recurring Basis [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets at fair value	66,817	97,670
Total liabilities at fair value	109,410	'
Fair Value Measurements, Recurring Basis [Member] | Derivative Liability [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities at fair value	109,410	'
Fair Value Measurements, Recurring Basis [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets at fair value	66,817	97,670
Level 1 [Member] | Fair Value Measurements, Recurring Basis [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets at fair value	66,817	97,670
Total liabilities at fair value	'	'
Level 1 [Member] | Fair Value Measurements, Recurring Basis [Member] | Derivative Liability [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities at fair value	'	'
Level 1 [Member] | Fair Value Measurements, Recurring Basis [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets at fair value	66,817	97,670
Level 2 [Member] | Fair Value Measurements, Recurring Basis [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets at fair value	'	'
Total liabilities at fair value	'	'
Level 2 [Member] | Fair Value Measurements, Recurring Basis [Member] | Derivative Liability [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities at fair value	'	'
Level 2 [Member] | Fair Value Measurements, Recurring Basis [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets at fair value	'	'
Level 3 [Member] | Fair Value Measurements, Recurring Basis [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets at fair value	'	'
Total liabilities at fair value	109,410	'
Level 3 [Member] | Fair Value Measurements, Recurring Basis [Member] | Derivative Liability [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total liabilities at fair value	109,410	'
Level 3 [Member] | Fair Value Measurements, Recurring Basis [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets at fair value	'	'

Fair_value_Measurements_Additi

Fair value Measurements - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013
Expense on derivative fair value assessment operations	$69,300	$69,300
Total liabilities at fair value	109,410	109,410
Convertible Senior Notes [Member]	'	'
Derivative liability	$40,110	$40,110

Fair_Value_Measurements_Assump

Fair Value Measurements - Assumptions used to Determine Initial Fair Value and Fair Value of Conversion Option Embedded in Convertible Senior Notes (Detail) (USD $)	0 Months Ended	12 Months Ended
	Nov. 18, 2013	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Stock Price	$4.47	$7.62
Risk fee Rate	1.33%	1.69%
Weights	'Equal weight	'Equal weight
Volatility	40.00%	40.00%
Initial Conversion Price	$5.36	$5.36
Remaining Time to Maturity	'5 years	'4 years 10 months 24 days
Minimum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Borrowing Cost	3.50%	3.50%
Credit spread	10.30%	9.30%
Maximum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Borrowing Cost	5.00%	5.00%
Credit spread	11.70%	11.70%

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail)

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

2014 [Member]

Each Year [Member]

DUEXIS [Member]

Sanofi-Aventis U.S [Member]

Sanofi-Aventis U.S [Member]

Sanofi-Aventis U.S [Member]

LODOTRA/RAYOS [Member]

Jagotec AG [Member]

AstraZeneca [Member]

AstraZeneca [Member]

Second Amendment for Lease Agreement [Member]

Reinach Office [Member]

Reinach Office [Member]

Mannheim Office [Member]

Mannheim Office [Member]

Deerfield, Illinois Office [Member]

Deerfield, Illinois Office Additional Facility [Member]

USD ($)

USD ($)

USD ($)

DUEXIS [Member]

First Quarter and Third Quarter of 2014 [Member]

USD ($)

First Quarter and Third Quarter of 2014 [Member]

USD ($)

USD ($)

CHF

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

DUEXIS [Member]

USD ($)

Amendments

sqft

sqft

USD ($)

sqft

Loss Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Area of lease agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

8,352

'

'

'

'

21,182

4,926

Date of entering into lease agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-13

'

'

'

'

30-Sep-11

31-Aug-12

Lease commencement date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1-Dec-11

'

Term of the lease expires

'

'

'

'

'

'

'

'

'

15-Apr-16

'

'

'

30-Jun-18

31-May-15

31-May-15

31-Dec-14

31-Dec-14

30-Jun-18

30-Jun-18

Minimum net rent, initially

'

'

'

'

'

'

'

'

'

'

'

'

'

$12,000

$7,000

6,000

$7,000

€ 5,000

$30,000

$7,000

Maximum rent after the fifth and sixth year by gradual increase each year

'

'

'

'

'

'

'

'

'

'

'

'

'

14,000

'

'

'

'

35,000

8,000

Option to extend term of lease

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

Number of amendments

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

Rent expense

463,000

458,000

507,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase commitment based on tablet and its pricing

'

'

'

'

'

10,286,000

'

'

'

3,351,000

'

'

'

'

'

'

'

'

'

'

Term of commitment made by the company to purchase tablets

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

Manufacturing and supply agreement initiation date

'

'

'

'

'

'

'2011-05

'

'

'2013-04

'2007-08

'2013-11

'

'

'

'

'

'

'

'

Binding purchase order issued

'

'

'

'

'

'

'

3,672,000

6,614,000

'

'

'

4,402,000

'

'

'

'

'

'

'

Royalty expense recognized in cost of goods sold

901,000

539,000

455,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty on net sales

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum annual royalty obligations

'

'

'

$5,000,000

$7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
DUEXIS [Member]	'
Legal Proceedings [Line Items]	'
License agreement generic entry date	1-Jan-23
Period to defend a patent infringement	'30 days
RAYOS [Member]	'
Legal Proceedings [Line Items]	'
Prevention period from approving the ANDA	'30 months

Debt_Agreements_Outstanding_De

Debt Agreements - Outstanding Debt Balances (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Convertible Senior Notes	$150,000	'
Senior Secured Loan	'	61,843
Current debt maturities	'	-11,935
Debt discount	-39,238	-13,042
Long-term debt, net of current maturities	$110,762	$36,866

Debt_Agreements_Additional_Inf

Debt Agreements - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 22, 2013

Jul. 31, 2013

Mar. 31, 2013

Feb. 29, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Dec. 31, 2013

Nov. 22, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 18, 2013

Nov. 18, 2013

Nov. 18, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Convertible Senior Notes [Member]

Convertible Senior Notes [Member]

Convertible Senior Notes [Member]

Convertible Senior Notes [Member]

Convertible Senior Notes [Member]

Convertible Senior Notes [Member]

Convertible Senior Notes [Member]

Convertible Senior Notes [Member]

Convertible Senior Notes [Member]

Common Stock [Member]

Options Purchased [Member ]

Option Sold [Member ]

Conversion Condition One [Member]

Conversion Condition Two [Member]

Conversion Condition Three [Member]

Call Option [Member]

Call Option [Member]

Trading_day

Trading_day

Trading_day

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior Secured Loan

'

'

'

'

'

'

'

$60,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate

'

'

'

'

'

'

'

17.00%

'

'

'

'

11.22%

5.00%

5.00%

'

'

'

'

'

'

Interest rate, cash payment

'

'

'

'

'

'

'

12.00%

12.00%

12.00%

'

'

'

'

'

'

'

'

'

'

'

Interest rate, debt increment

'

'

'

'

'

'

'

5.00%

5.00%

5.00%

'

'

'

'

'

'

'

'

'

'

'

Interest expenses at 5%

'

'

'

'

'

'

'

'

3,001,000

1,842,000

'

'

'

'

'

'

'

'

'

'

'

Common stock issued to the lenders

66,097,417

66,097,417

61,722,247

'

'

'

'

'

1,250,000

'

'

'

'

'

'

13,164,951

'

'

'

'

'

Debt discount

'

'

'

'

'

'

'

'

5,075,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, periodic payment principal

'

'

'

'

'

'

'

3,978,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of long term debt

'

'

'

'

'

5,761,000

5,836,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt payment, principal amount

'

'

'

'

'

'

3,978,000

'

'

'

3,978,000

'

'

'

'

'

'

'

'

'

'

Debt payment, interest amount

'

'

'

'

'

'

1,858,000

'

'

'

1,783,000

'

'

'

'

'

'

'

'

'

'

Number of warrants issued

'

'

'

'

'

'

'

3,277,191

'

'

'

'

'

'

'

'

'

'

'

'

'

Subsidiary percentage ownership

'

'

'

'

'

'

'

65.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

'

'

'

'

0.01

'

'

'

'

'

'

'

'

'

Repayment of notes payable

'

64,844,000

19,788,000

13,067,000

70,409,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on extinguishment of debt

'

'

'

'

26,404,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Senior Notes

150,000,000

150,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000,000

'

'

'

'

'

Net proceeds received

'

'

'

'

'

'

'

'

'

'

'

'

143,598,000

'

'

'

'

'

'

'

'

Notes fees

'

'

'

'

'

'

'

'

'

'

'

'

6,402,000

'

'

'

'

'

'

'

'

Notes expenses

'

'

'

'

'

'

'

'

'

'

'

'

18,675,000

'

'

'

'

'

'

'

'

Maturity date of debt instrument

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15-Nov-18

'

'

'

'

'

'

Strike price, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.364

6.705

'

'

'

Convertible Senior Notes sold, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

Number of options underlaying capped call

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

Amount of debt instrument equivalent to options underlaying capped call

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

1,000,000

'

'

'

'

'

'

Initial conversion, number of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

186.428

'

'

'

'

'

'

Initial conversion price, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.36

$5.36

'

'

'

'

'

'

Convertible senior notes, principal payment

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

1,000,000

'

'

'

'

1,000

'

Percentage of common stock outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19.99%

'

'

'

'

'

Debt Instrument consecutive trading days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'5 days

'10 days

Debt Instrument number of trading days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20

5

45

Debt Instrument convertible minimum percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

130.00%

'

10.00%

Debt Instrument convertible maximum percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

98.00%

'

Percentage of principal amount of debt instrument to be repurchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

Derivative liability

'

'

'

'

'

'

'

'

'

'

'

'

40,110,000

'

'

'

'

'

'

'

'

Expense on derivative fair value assessment operations

69,300,000

69,300,000

'

'

'

'

'

'

'

'

'

'

'

69,300,000

69,300,000

'

'

'

'

'

'

Total liabilities at fair value

$109,410,000

$109,410,000

'

'

'

'

'

'

'

'

'

'

'

$109,410,000

$109,410,000

'

'

'

'

'

'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Subsidiary, Sale of Stock [Line Items]	'	'	'	'
Gross proceeds, common stock	'	$639	$441	$124
Number of warrants exercised	1,365,497	'	'	'
Common stock issued in a cashless exercise	1,360,746	'	'	'
Cowen [Member]	'	'	'	'
Subsidiary, Sale of Stock [Line Items]	'	'	'	'
Common stock, shares issued	'	2,448,575	'	'
Gross proceeds, common stock	'	$6,238	'	'

Equity_Incentive_Plans_Additio

Equity Incentive Plans - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jul. 28, 2011

Dec. 31, 2013

Dec. 05, 2013

Nov. 16, 2013

Nov. 07, 2013

Jan. 02, 2012

Jul. 28, 2011

Jan. 02, 2011

Mar. 03, 2014

Jan. 10, 2014

Dec. 31, 2013

Dec. 05, 2013

Jul. 28, 2011

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Forecast [Member]

2005 Plan [Member]

2011 EIP [Member]

2011 EIP [Member]

2011 EIP [Member]

2011 EIP [Member]

2011 EIP [Member]

2011 EIP [Member]

2011 EIP [Member]

2011 EIP [Member]

2011 EIP [Member]

2011 ESPP [Member]

2011 ESPP [Member]

2011 ESPP [Member]

Executive Officers [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares reserved for future issuance

'

'

'

'

'

'

460,842

674,400

1,474,304

800,000

200,000

'

3,366,228

'

730,000

'

412,805

'

463,352

Percentage of common stock shares outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.00%

Common stock, shares outstanding

'

'

'

'

'

'

'

'

'

'

'

1,474,304

'

'

'

'

'

'

1,053,074

Minimum payroll deduction to purchase shares of common stock under 2011 ESPP

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

Maximum payroll deduction to purchase shares of common stock under 2011 ESPP

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

Employees purchase shares of common stock at price per share equal

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

Lower of fair market (offering period)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

Additional reserve of common stock for issuance

'

'

'

'

'

'

'

78,795

'

'

'

'

1,600,673

'

'

703,400

'

1,053,074

'

Common stock, shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

350,547

'

'

Common stock shares authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

412,805

'

'

Option grants under plan

2,158,950

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for future issuance upon exercise of options outstanding

4,411,080

2,746,918

'

'

'

'

'

'

'

'

'

'

1,304,713

'

'

'

'

'

'

Number of common stock share added each year in percentage

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

Exercise price of stock options percentages of the fair market value on the date of grant

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

Exercise price of stock options

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

Options granted to purchase common stock

2,158,950

516,325

1,256,339

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average fair value of options granted to purchase common stock

$2.84

$3.44

$5.77

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted shares granted to employees to purchase common stock

730,000

520,000

304,890

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock units, vesting period

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted, Number of Units

'

'

'

831,004

101,004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Tax benefit recognized from stock-based compensation expense

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Tax benefits realized from stock options exercised

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-tax unrecognized compensation expense for all unvested share-based awards

7,459

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-tax compensation expense for all unvested share-based awards, recognized in 2014

'

'

'

'

'

$5,792

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity_Incentive_Plans_Summary

Equity Incentive Plans - Summary of Stock Options Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Options, Outstanding Beginning Balance	2,746,918	'	'
Options, Granted	2,158,950	'	'
Options, Exercised	-41,820	'	'
Options, Forfeited	-452,968	'	'
Options, Outstanding Ending Balance	4,411,080	2,746,918	'
Options, Exercisable as of December 31, 2013	2,079,728	'	'
Weighted Average Exercise Price, Outstanding Beginning Balance	$8.85	'	'
Weighted Average Exercise Price, Granted	$2.84	$3.44	$5.77
Weighted Average Exercise Price, Exercised	$3.88	'	'
Weighted Average Exercise Price, Forfeited	$3.88	'	'
Weighted Average Exercise Price, Outstanding Ending Balance	$6.47	$8.85	'
Weighted Average Exercise Price, Exercisable as of December 31, 2013	$9.57	'	'
Weighted Average Remaining Contractual Term, Outstanding as of December 31, 2013	'7 years 10 months 24 days	'	'
Weighted Average Remaining Contractual Term, Exercisable as of December 31, 2013	'6 years 9 months 18 days	'	'
Average Intrinsic Value, Outstanding as of December 31, 2013	$13,283	'	'
Average Intrinsic Value, Exercisable as of December 31, 2013	$3,860	'	'

Equity_Incentive_Plans_Summary1

Equity Incentive Plans - Summary of Outstanding Stock Options (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding, Number of options outstanding	4,411,080	'
Options Outstanding, Weighted Average Exercise price	$6.47	$8.85
Options Outstanding, Weighted Average Remaining Contractual Term	'7 years 10 months 24 days	'
Options Exercisable, Number Exercisable	2,079,728	'
Options Exercisable, Weighted Average Exercise Price	$9.57	'
Exercise Price Ranges, $1.36 - $3.97 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Prices, Lower Range	$1.36	'
Range of Exercise Prices, Upper Range	$3.97	'
Options Outstanding, Number of options outstanding	2,079,203	'
Options Outstanding, Weighted Average Exercise price	$2.63	'
Options Outstanding, Weighted Average Remaining Contractual Term	'9 years 1 month 6 days	'
Options Exercisable, Number Exercisable	432,699	'
Options Exercisable, Weighted Average Exercise Price	$2.65	'
Exercise Price Ranges, $4.10 - $5.20 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Prices, Lower Range	$4.10	'
Range of Exercise Prices, Upper Range	$5.20	'
Options Outstanding, Number of options outstanding	1,039,318	'
Options Outstanding, Weighted Average Exercise price	$4.98	'
Options Outstanding, Weighted Average Remaining Contractual Term	'7 years 6 months	'
Options Exercisable, Number Exercisable	651,196	'
Options Exercisable, Weighted Average Exercise Price	$5.02	'
Exercise Price Ranges, $7.48 - $12.94 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Prices, Lower Range	$7.48	'
Range of Exercise Prices, Upper Range	$12.94	'
Options Outstanding, Number of options outstanding	935,627	'
Options Outstanding, Weighted Average Exercise price	$10.04	'
Options Outstanding, Weighted Average Remaining Contractual Term	'7 years	'
Options Exercisable, Number Exercisable	645,136	'
Options Exercisable, Weighted Average Exercise Price	$11.01	'
Exercise Price Ranges, $13.47 - $17.22 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Prices, Lower Range	$13.47	'
Range of Exercise Prices, Upper Range	$17.22	'
Options Outstanding, Number of options outstanding	106,568	'
Options Outstanding, Weighted Average Exercise price	$13.91	'
Options Outstanding, Weighted Average Remaining Contractual Term	'5 years 7 months 6 days	'
Options Exercisable, Number Exercisable	104,547	'
Options Exercisable, Weighted Average Exercise Price	$13.85	'
Exercise Price Ranges, $20.78 - $28.83 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Prices, Lower Range	$20.78	'
Range of Exercise Prices, Upper Range	$28.83	'
Options Outstanding, Number of options outstanding	250,364	'
Options Outstanding, Weighted Average Exercise price	$28.05	'
Options Outstanding, Weighted Average Remaining Contractual Term	'6 years 6 months 4 days	'
Options Exercisable, Number Exercisable	246,150	'
Options Exercisable, Weighted Average Exercise Price	$28.18	'

Equity_Incentive_Plans_Weighte

Equity Incentive Plans - Weighted Average Fair Value per Share of Stock Option Awards Granted and Assumptions Used to Value Stock Options (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Dividend yield	'	'	'
Risk-free interest rate	1.20%	1.00%	1.20%
Weighted average volatility	86.70%	89.00%	89.30%
Expected life (in years)	'5 years 11 months 23 days	'5 years 11 months 16 days	'6 years
Weighted average grant date fair value per share of options granted	$2.80	$2.50	$4.20

Equity_Incentive_Plans_Summary2

Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Detail) (Restricted Stock Units (RSUs) [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Restricted Stock Units (RSUs) [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Outstanding as of December 31, 2012, Number of Units	232,158
Granted, Number of Units	831,004
Vested, Number of Units	-174,213
Forfeited, Number of Units	-55,948
Outstanding as of December 31, 2013, Number of Units	833,001
Unvested share outstanding, Weighted Average Grant-Date Fair Value Per Units	$4.92
Granted, Weighted Average Grant-Date Fair Value Per Units	$2.95
Vested, Weighted Average Grant-Date Fair Value Per Units	$6.05
Forfeited, Weighted Average Grant-Date Fair Value Per Units	$2.86
Unvested share outstanding, Weighted Average Grant-Date Fair Value Per Units	$2.86

Equity_Incentive_Plans_Summary3

Equity Incentive Plans - Summary of Share-Based Compensation Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'
Net effect of stock-based compensation expense on net loss	$5,014	$4,661	$2,530
Research and Development [Member]	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'
Net effect of stock-based compensation expense on net loss	1,054	1,186	760
Sales and Marketing [Member]	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'
Net effect of stock-based compensation expense on net loss	1,465	1,090	451
General and Administrative [Member]	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'
Net effect of stock-based compensation expense on net loss	$2,495	$2,385	$1,319

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Related Party Transactions [Abstract]	'	'	'
Consulting fees to related parties	$691	$716	$678

Income_Taxes_Components_of_Ben

Income Taxes - Components of Benefit for Income Tax (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current provision	'	'	'
Current Income Tax Expense Benefit	$47	$39	$31
Deferred benefit	'	'	'
Deferred Income Tax Expense Benefit	-1,168	-5,210	-14,714
Effective income taxes	-1,121	-5,171	-14,683
State [Member]	'	'	'
Current provision	'	'	'
Current Income Tax Expense Benefit	4	4	3
Foreign [Member]	'	'	'
Current provision	'	'	'
Current Income Tax Expense Benefit	43	35	28
Deferred benefit	'	'	'
Deferred Income Tax Expense Benefit	($1,168)	($5,210)	($14,714)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jul. 26, 2012	Jul. 26, 2012	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Line Items]	'	'	'	'	'	'	'
Total benefit for income taxes	'	'	'	'	$1,121	$5,171	$14,683
Decrease in the income tax benefit	'	'	'	'	4,050	'	'
Reclassification of asset	35,456	35,456	'	'	'	0	'
Release in valuation allowance	'	'	4,258	'	'	4,258	'
Intangible impairment charge	'	'	'	69,621	'	'	69,621
Increase in the deferred tax valuation allowance	'	'	'	'	32,452	27,776	14,213
Net operating loss	'	'	'	'	995	'	'
Original issuance discount related to capped call	'	'	'	'	6,740	'	'
Accrued interest or penalties	'	'	'	'	0	0	'
Minimum [Member]	'	'	'	'	'	'	'
Income Taxes [Line Items]	'	'	'	'	'	'	'
Operating loss carryforward, expiration year	'	'	'	'	'2015	'	'
Maximum [Member]	'	'	'	'	'	'	'
Income Taxes [Line Items]	'	'	'	'	'	'	'
Operating loss carryforward, expiration year	'	'	'	'	'2025	'	'
Federal [Member]	'	'	'	'	'	'	'
Income Taxes [Line Items]	'	'	'	'	'	'	'
Net operating loss carryforwards	'	'	'	'	275,430	'	'
State [Member]	'	'	'	'	'	'	'
Income Taxes [Line Items]	'	'	'	'	'	'	'
Net operating loss carryforwards	'	'	'	'	123,257	'	'
Foreign [Member]	'	'	'	'	'	'	'
Income Taxes [Line Items]	'	'	'	'	'	'	'
Net operating loss carryforwards	'	'	'	'	91,804	'	'
Research Tax Credit Carryforward [Member] | Federal [Member]	'	'	'	'	'	'	'
Income Taxes [Line Items]	'	'	'	'	'	'	'
Income tax credit carryforwards	'	'	'	'	2,745	'	'
Income tax credit carryforwards, expiration year	'	'	'	'	'2026	'	'
Research Tax Credit Carryforward [Member] | State [Member]	'	'	'	'	'	'	'
Income Taxes [Line Items]	'	'	'	'	'	'	'
Income tax credit carryforwards	'	'	'	'	394	'	'
Fiscal Year 2014 [Member]	'	'	'	'	'	'	'
Income Taxes [Line Items]	'	'	'	'	'	'	'
Operating loss carryforward annual limitation	'	'	'	'	49,893	'	'
Fiscal Year 2015 [Member] | Minimum [Member]	'	'	'	'	'	'	'
Income Taxes [Line Items]	'	'	'	'	'	'	'
Operating loss carryforward annual limitation	'	'	'	'	22,001	'	'
Fiscal Year 2016 [Member] | Minimum [Member]	'	'	'	'	'	'	'
Income Taxes [Line Items]	'	'	'	'	'	'	'
Operating loss carryforward annual limitation	'	'	'	'	$22,001	'	'

Income_Taxes_Companys_of_Loss_

Income Taxes - Company's of Loss Before Benefit for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
United States	($139,347)	$56,038	($43,148)
International	-10,779	-149,003	-84,800
Loss before benefit for income taxes	($150,126)	($92,965)	($127,948)

Income_Taxes_Reconciliation_Be

Income Taxes - Reconciliation Between Statutory Federal Income Tax and Effective Tax (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
U.S. federal income taxes at statutory tax rate	($52,543)	($32,538)	($44,781)
Stock based compensation	1,107	1,063	658
Foreign tax rate differential	2,019	4,376	14,994
Deferred taxes not benefited	23,921	21,715	14,499
Derivative liability	24,255	'	'
Research and development credit	120	-5	-79
Other	'	218	26
Effective income taxes	($1,121)	($5,171)	($14,683)

Income_Taxes_Deferred_Tax_Asse

Income Taxes - Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Deferred tax assets:	'	'	'	'
Net operating loss carryforwards	$121,001	$97,724	$68,689	'
Derivative liability	14,799	'	'	'
Accruals and reserves	7,073	5,144	1,906	'
Original issuance discount related to capped call	6,740	'	'	'
Contingent royalties	3,122	'	'	'
Research and development credits	2,571	2,445	2,447	'
Foreign intangible assets	63	76	90	'
Total deferred tax assets	155,369	105,389	73,132	'
Valuation allowance	-128,422	-95,970	-68,194	-53,981
Deferred tax assets, net of valuation allowance	26,947	9,419	4,938	'
Deferred tax liabilities:	'	'	'	'
Debt discount	14,477	'	'	'
In-process research and development	'	'	7,354	'
Developed technology	13,009	13,827	7,145	'
Intangible assets	2,823	'	'	'
Total deferred tax liabilities	30,309	13,827	14,499	'
Net deferred income tax liability	$3,362	$4,408	$9,561	'

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Beginning and Ending Amounts of Valuation Allowance (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'	'
Beginning Balance	'	($95,970)	($68,194)	($53,981)
Increase for current year activity	'	-32,452	-32,034	-14,213
Release in valuation allowance	4,258	'	4,258	'
Ending Balance	'	($128,422)	($95,970)	($68,194)

Income_Taxes_Reconciliation_of1

Income Taxes - Reconciliation of Beginning and Ending Amounts of Valuation Allowance (Parenthetical) (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Release in valuation allowance	$4,258	$4,258

Income_Taxes_Changes_in_Uncert

Income Taxes - Changes in Uncertain Income Tax Positions (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Beginning balance	$442	$442	$424
Additions	51	2	34
Reductions	'	'	'
Unrecognized Tax Benefits, Current Year Tax Positions	51	2	34
Additions	'	'	'
Reductions	-2	-2	-16
Settlements	'	'	'
Lapses in statutes of limitations	'	'	'
Additions from current year acquisitions	'	'	'
Unrecognized Tax Benefits Income Tax Prior Period Tax Positions	-2	-2	-16
Ending balance	$491	$442	$442

Employee_Benefit_Plans_Additio

Employee Benefit Plans - Additional information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Defined benefit plan expenses	$0	$0	$0
Defined Benefit Plan [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Defined benefit plan expenses	$52	$52	$55

Selected_Quarterly_Financial_I2

Selected Quarterly Financial Information (Unaudited) - Summary of Selected Financial Results of Operations (Detail) (USD $)	3 Months Ended								6 Months Ended	9 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Jun. 30, 2013	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'	'	'	'	'	'	'	'	'	'	'
Net sales	$30,080	$24,112	$11,131	$8,693	$6,359	$6,319	$3,681	$2,485	$19,824	$43,936	$74,016	$18,844	$6,927
Gross profit	24,825	20,905	8,737	4,924	2,816	2,711	986	456	'	'	59,391	6,969	-340
Loss from operations	-5,762	-2,744	-15,804	-18,544	-22,026	-18,714	-18,345	-19,788	'	'	-42,854	-78,873	-120,641
Net loss	($102,901)	($5,492)	($18,441)	($22,171)	($24,333)	($16,953)	($22,782)	($23,726)	'	'	($149,005)	($87,794)	($113,265)
Net loss per common share-basic and diluted	($1.56)	($0.08)	($0.29)	($0.36)	($0.40)	($0.47)	($0.68)	($0.98)	'	'	($2.34)	($2.26)	($12.56)

Selected_Quarterly_Financial_I3

Selected Quarterly Financial Information (Unaudited) - Summary of Selected Financial Results of Operations (Parenthetical) (Detail) (USD $)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Jun. 30, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Selected Quarterly Financial Data [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Net sales

$30,080

$24,112

$11,131

$8,693

$6,359

$6,319

$3,681

$2,485

$19,824

$43,936

$74,016

$18,844

$6,927

As Reported [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

Selected Quarterly Financial Data [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Net sales

'

$26,218

$12,254

$9,171

$6,747

$6,521

$3,841

$2,523

$21,425

$47,643

'

'

'